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SUMMARY 
  
 Atherosclerosis is an inflammatory disease, occurring preferentially in arterial 
regions with disturbed flow.  We have shown that disturbed flow induces inflammation in 
endothelial cells (ECs) by producing bone morphogenic protein-4 (BMP4). Moreover, 
chronic BMP4 infusion induces endothelial dysfunction and systemic hypertension in 
mice. Here, we examined which BMP receptors (BMPR) mediate BMP4 action in ECs. 
Western blot, immunostaining and RT-PCR studies using human and bovine ECs, mouse 
aortas and human coronary arteries (HCA) showed that BMPRI (ALK2 and 6) and BMP-
RII were expressed in ECs.  As a functional test, ECs were treated with a BMPRII siRNA 
to knockdown expression. BMPRII knockdown blocked a well-known BMP4 response - 
smad1/5/8 phosphorylation, as expected. Unexpectedly, BMPRII knockdown itself 
significantly stimulated ICAM-1 and VCAM-1 expression and monocyte adhesion in a 
BMP4-independent manner.  Inflammatory responses caused by BMPRII knockdown 
were blocked by inhibitors of NADPH oxidase and NFκB.  From these results, we 
hypothesized that BMPRII knockdown in ECs would cause inflammation, which is a 
critical event in atherosclerosis initiation and progression.  Genetic mutations of BMPRII 
have been linked to primary pulmonary hypertension. However, it is not known whether 
BMP-RII is regulated by atherosclerotic conditions and plays a role in non-pulmonary 
vessels causing inflammation and atherosclerosis. We examined BMPRII levels in HCA 
by immunostaining. While non-diseased arteries showed intense staining of BMPRII, the 
expression decreased as lesions became more advanced.  BMPRII was virtually 
undetectable in the most advanced lesions. These findings suggested a potential link 
 xiv
between pro-atherosclerotic conditions and BMP-RII levels. We tested this hypothesis by 
treating ECs with pro-inflammatory cytokines found in atheromas: TNFα decreased 
BMPRII by 2-fold.  In contrast, statins increased BMPRII by 4-fold. In summary, we 
demonstrate for the first time that BMPRII can be down- or up-regulated by pro- or anti-
atherogenic conditions, respectively, and it is dramatically decreased in HCA with 
advanced plaques. Moreover, BMPRII knockdown in ECs induces inflammation, a 
critical atherogenic step. We propose that focal inflammation initiated by disturbed flow, 
together with circulating pro-atherogenic risk factors, may lead to a vicious cycle of 
BMPRII down-regulation causing secondary inflammation and atheroma progression.  
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CHAPTER 1 
INTRODUCTION 
 
 Cardiovascular disease has been a leading cause of death in recent years, and 
atherosclerosis has been implicated in 75% of these deaths. To develop treatments for this 
widespread pathology, research has focused on finding the causes and mechanisms of this 
disease. It has been well established that hemodynamic factors affect atherosclerosis. Our 
work has shown that bone morphogenetic protein 4 (BMP4) may be an important protein 
in shear stress-induced endothelial dysfunction and atherogenesis.  The following review 
will focus on this emerging field of shear stress, BMP4, BMP receptors (BMPR), 
inflammation and atherosclerosis. 
 
Atherosclerosis  
Atherosclerosis is a major cause of cardiovascular disease, including coronary 
artery disease, chronic heart failure, peripheral artery disease, chronic renal failure and 
stroke. It is characterized by a long process of plaque development that begins decades 
before clinical manifestation 1,2. There is no doubt that the complex pathogenesis of 
atherosclerosis cannot be ascribed to a single factor. Environmental, genetic, and 
hemodynamic factors all play a part in its development. At the cellular level, a large 
number of growth factors, cytokines and vaso-regulatory molecules participate in this 
process 3.   
While there are several well-known systemic risk factors causing atherosclerosis, 
such as smoking, diabetes, high cholesterol, oxidative stress, and obesity, one of its key 
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features is the focal developmental pattern of plaques.  Both systemic factors and local 
hemodynamic factors are responsible for endothelial dysfunction, which is characterized 
by a shift in the actions of the endothelium toward reduced vasodilation, a 
proinflammatory state, and prothrombotic properties4. Atherosclerotic plaques typically 
occur in branched or curved arterial regions where endothelial cells (ECs) are exposed to 
disturbed flow conditions such as low and oscillatory shear stress 5,6.  In contrast, the 
straight arterial regions exposed to laminar shear stress are well-protected from 
atherosclerosis development 5,6.  
 
Atherosclerotic Plaque Formation 
Atherosclerosis is now known as an inflammatory disease. Endothelial 
dysfunction is caused by both systemic and local factors that promote inflammation, and 
it is an important early event in the pathogenesis of atherosclerosis, contributing to plaque 
initiation and progression. The development of lesions includes a series of highly specific 
cellular and molecular responses that can best be described as chronic inflammation. The 
process begins with immune cells (monocytes and T lymphocytes) binding to activated 
endothelium and secreting cytokines 7,8. Monocytes bind via the cell adhesion molecules, 
ICAM-1 and VCAM-1, and enter the blood vessel wall. Following transmigration, they 
differentiate into macrophages, take up lipoproteins, transform into foam cells, and 
eventually rupture and release their contents back into the sub-intimal space 7.  
Cytokines, such as IL-1β and IFN-γ, released from macrophages and foam cells 
accelerate inflammation. They also reach smooth muscle cells in the medial layer and 
promote proliferation.  Positive feedback continues as they have internalized too many 
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lipoproteins and released all of their contents into the advancing plaque region until 
eventual plaque rupture. Plaque rupture is a dangerous condition that may result in a heart 
attack or stroke. After the rupture, the site of the rupture could seal over with an 
overlying clot, causing a potentially larger blockage in the artery. Also, the fatty particles 
may become accumulated further downstream in the artery.  
 
Atherosclerosis and Hemodynamics 
Cardiovascular disease and hemodynamics have been linked for the past two 
decades.  Endothelial cells lining the blood vessel wall serve several functions. They 
inhibit platelet aggregation and coagulation, selectively transport macromolecules from 
the blood into the vessel wall, and sense blood flow. As described, blood flow profiles 
determine the site specificity of atherosclerotic plaque development. In 1969, Caro et al. 
identified the important correlation between low shear stress and atherosclerosis9. Zarins 
and colleagues modeled the human carotid bifurcation and  correlated the localization of 
plaques to areas of flow disruption 6,10. Similar modeling was performed on the 
abdominal aorta. In this area, oscillating flow and low shear stress were observed along 
the posterior wall of the infrarenal aorta where atherosclerotic lesions develop 11. It was 
hypothesized that this low and oscillatory shear stress causes endothelial dysfunction by 
increasing the relative residence time of lipoproteins and inflammatory cells. Endothelial 
cell responsiveness to flow is essential for normal vascular function and plays a role in 
the development of atherosclerosis. Much research has shown that ECs respond 
differently to different types of shear stress, in both structure and function. They change 
their cell morphology through changes in the cytoskeleton and also exhibit the different 
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gene expression profiles of the endothelial cell itself 12. Via en face tissue staining from 
mouse aorta, Hajra et al. showed that EC morphology  varies in athero prone versus 
athero protected  regions of the vasculature13. Orientation of endothelial cells was more 
random and cell shape was more variable in athero prone regions with NFκ-B, ICAM-1, 
and VCAM-1 expression, whereas ECs aligned and were elongated with the direction of 
the blood flow in athero protected regions without adhesion molecule expression. All of 
these indicate that ECs sense shear stress and actively respond to it.  
 
Shear Stress and Endothelial Cell Biology 
Shear stress is defined as a tangential force over a surface area. In the vasculature, 
this corresponds to the dragging force of blood as it flows over the blood vessel wall. 
Mathematically, shear stress can be described as that the shear stress at the wall is 
proportional to the viscosity of the blood and the velocity gradient:   
 
τ = µ du/dr 
 
 and can be described by  
 
τwall = 32µQ 
          πD3 
 
for steady laminar flow in a straight tube  (τ: shear stress, µ: viscosity, u: velocity, r: 
radius, Q: volume, D: diameter) 14 . 
 
To investigate the effects of hemodynamic flow on endothelial cells in a 
controlled manner, several in vitro devices, such as the parallel plate 15, vertical-step flow 
chamber 16, cone- and-plate 17, and modified cone-and-plate 18,  were developed  19. ECs 
grown in vitro under static conditions have a “cobble stone” cell shape with a random 
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orientation. When these cells are subject to uni-directional fluid flow, they elongate and 
align in the direction of flow 20,21 . However, under oscillatory flow with a net zero shear 
stress, they do not align and retain the morphology of cells under static conditions 15. 
These in vitro studies using cell culture systems correspond well to the in vivo 
observations made by Hajra et al. as described above13.  
Several mechanotransduction pathways have been suggested, including integrins, 
ion channels, caveolae, G protein-linked receptors, mitogen-activated protein (MAP) 
kinase signaling, and the cytoskeleton 22,23. In addition to changes in cell morphology, 
shear stress activates ion channels instantly, and in a more delayed manner, changes gene 
expression profiles19. Many groups, including ours, have performed microarray analyses 
and have identified gene expression profiles that are activated under various types of 
shear stress 24-27. In addition, efforts to explain gene regulation by flow have led to the 
identification of promoter sequences termed SSRE (shear stress responsive elements). 
However, little is understood about the crosstalk between these elements and their bound 
transcription factors for each shear stress-regulated gene. Nitric oxide (NO), a 
vasodilator, intracelleular calcium and PKC-ε are activated with unidirectional laminar 
flow 28-30. MAP kinase ERK and JNK are phosphorylated in a shear dependent manner 31-
34. 
 In the case of oscillatory shear stress, many studies have focused on inflammatory 
responses including adhesion molecule expression and ROS stimulation 35-39. Oxidative 
stress has been implicated in the development of numerous diseases including premature 
aging, cancer, neurodegenerative diseases, and atherosclerosis 40. The reactive oxygen 
species (ROS) superoxide (O2·-), hydrogen peroxide (H2O2), and peroxynitrite (ONOO·-) 
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contribute significantly to such stress and have been intimately linked to atherogenesis 
via inflammatory responses that result from disturbed flow conditions 41-43.  We have 
previously shown that OS increases ROS levels in endothelial cells, while LS reduces 
ROS compared to static controls.  OS stimulation of ROS leads to ICAM-1 expression 
and monocyte adhesion, an early and critical atherogenic event 44,45.  Furthermore, we 
have discovered one mechanosensitive gene, BMP4, that is produced by OS stimulation 
and acts as a potent inflammatory cytokine 17. BMP4 protein is easily detected in 
endothelial cells cultured under static conditions. Expression is increased further by OS 
(1 day) and inhibited by LS exposure (1 day) 17. The significance of this shear sensitive 
BMP4 expression was also supported by the finding that BMP4 protein is expressed in 
endothelial cells overlying foam cell lesions, but not in the normal “minimally diseased” 
areas of the human coronary arteries 17.  Furthermore, ICAM-1 staining, but not VCAM-
1, is selectively increased in the similar endothelial patches expressing BMP4.  While the 
immunohistochemical detection of BMP4 protein needs additional studies such as in-situ 
mRNA hybridization, to examine whether BMP4 is indeed produced by endothelial cells, 
these results are consistent with previous findings reported in another study using human 
carotid arteries with atherosclerosis 46.  
 
Bone Morphogenetic Protein (BMP) 
BMP was originally discovered as a bone-inducing protein 47. Its critical and diverse roles 
now include embryonic development, patterning, cartilage formation, and cell 
differentiation 48,49. BMPs are members of the transforming growth factor-β (TGF-β) 
superfamily. This superfamily consists of TGF-βs, inhibins, bone morphogenetic 
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proteins, growth differentiation factors, anti-mullerian hormone, activins, and myostatin 
48. More than 30 BMP proteins have been identified, and BMP2/4 and BMP5/6/7 classes 
are the best characterized members.   
 
Figure 1.1. The structure of BMPs. (A) Schematic diagram of BMPs. (B) Three 
dimensional structure of BMP2 and BMP receptor IA and IB. This figure is taken from 
the review paper of Xiao et al50 .   
 
In particular, BMP4 has been identified as a protein that induces ectopic bone and 
cartilage formation when implanted in rats 48. It is synthesized as a 408 amino acid 
precursor (pre-pro-precursor) that is proteolytically cleaved in the Golgi apparatus by 
pre-proconvertases such as furin that recognize the motif RRXR 51. This leaves a C-
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terminal mature protein (116 amino acids) that has seven conserved cysteine residues. 
Figure 1.1 describes that BMPs synthesized as three domains and leaves mature peptide 
after the cleavage50. BMP4 is a secreted glycoprotein that can also dimerize. BMP4 is 
secreted as a 36 kDa pre-form, an 18 kDa monomer when glycosylated, and a 23 kDa 
dimer in a reduced condition 52.  BMP4 forms a homodimer when binding to its 
receptors, but there is a report that recombinant heterodimer between BMP4 and BMP7 is 
more potent in bioassays than BMP4 or BMP7 homodimers 53.  
 Unlike TGF-β, BMPs are secreted as active proteins and their activities are 
counterbalanced by secreted antagonists such as noggin and chordin 54. BMP4 directly 
binds with high affinity to chordin (Kd= 300 pM) or noggin (Kd= 20 pM) 55. Binding of 
BMP4 to noggin or chordin prevents it from binding to its cognate receptor.  Although 
BMP7 can also interact with noggin, it does so with very low affinity 56. Noggin and 
chordin do not bind TGF-β1 or activin 57. Due to its relative specificity, noggin has been 
used as a valuable tool to dissect BMP4 function in cells and tissues 37.  
 The role of BMPs in vascular endothelial cells is an area of active research. BMP 
expression was shown to be increased in atherosclerotic plaques, although these authors 
did not address the involvement of ECs 58. In ECs, BMP6 was reported to induce 
angiogenesis 59,60.  In addition, hypoxia and VEGF up-regulate BMP2 mRNA and protein 
expression in microvascular endothelial cells 61. TNF-α increased BMP2 mRNA 
expression, and administration of H2O2 and high intravascular pressure also increased 
NFκB activation and BMP2 expression 62.  BMP4 mediates apoptosis of capillary 
endothelial cells 63. Shin et al. 64 showed BMP4 produced by endothelial cells modulates 
osteogenesis in calcifying vascular cells.  
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Through microarray studies and additional functional studies, our lab has found 
that oscillatory shear stress induces BMP4 expression in endothelial cells compared to the 
laminar shear stress. Under the static condition, BMP4 level was highly expressed, and 
OS increased BMP4 expression about 10% compared to static.  BMP4 triggers a cascade 
of inflammatory responses including monocyte adhesion to endothelial cells.  In addition, 
we have found that BMP4 expression is indeed increased in the endothelial cells 
overlying early atherosclerotic lesions in human coronary arteries 17,58.  
 
 BMP Receptors  
 BMPs bind to their receptors (BMPRs) to relay intracellular signaling. There are 
two types of signaling receptors specific for BMPs: BMP type I receptors (BMPRI) and 
type II receptors (BMPRII). Both are required for BMP signaling 56. Three BMP type I 
receptors, BMPRIA (also known as ALK3, Activin-Like Kinase-3), BMPRIB (ALK6), 
and ALK2, as well as three type II receptors (BMPRII, Activin Receptor II (ActRII), and 
ActRIIB) have been identified 65. Although somewhat variable depending upon species 
and vascular bed-origins, endothelial cells from mouse arteries as well as cultured murine 
and bovine aortic endothelial cells have been shown to express both type I (ALK2, 3, and 
6) and type II BMPRs 66. Unlike their well-known effects in bone formation and 
embryonic development, the functional importance of BMPRs in the vascular wall is an 
area of increasing attention in research.  In endothelial cells, transfection with 
constitutively active mutants of ALK2, ALK3, and ALK6 has been shown to stimulate 
expression of the id gene and angiogenic responses 66. One notable exception is in 
vascular smooth muscle cells where the loss-of-function mutations of BMPRII have been 
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linked to familial primary pulmonary hypertension and sporadic primary pulmonary 
hypertension in humans 67. In addition, it has been reported that BMPRII expression is 
reduced in the lungs of the primary pulmonary hypertension patients despite the lack of 
detectable mutations of the receptor 68. Primary pulmonary hypertension (PPH) is 
characterized by obliteration of pre-capillary pulmonary arteries, leading to sustained 
elevation of pulmonary arterial pressure and subsequent right ventricular hypertrophy. 
PPH is typically associated with abnormal proliferation of endothelial and smooth muscle 
cells within the small pulmonary arteries 69.  
BMP pseudoreceptor and co-receptor have also been identified. BMP and activin 
membrane-bound inhibitor (BAMBI) was cloned as a BMP pseudoreceptor that lacks an 
intracellular kinase domain, preventing the formation of a receptor complex 70.  In human 
colorectal tumors, activation and accumulation of β-catenin increased BAMBI 
expression. It seems that overexpressed BAMBI inhibits TGF-β-mediated growth arrest, 
and this may contribute to colorectal tumorigenesis 71. Also, BMP co-receptor DRAGON 
(the glycosylphosphatidylinositol (GPI)-anchored protein) was recently identified 72,73. 
DRAGON has the ability to bind to BMP2, BMPRIA and BMPRIB.  
 
Intracellular Signaling of BMPs.   
BMPs bind to BMPRII inducing homo-dimerization and auto-phosphorylation 74. 
The dimerized type II receptor phosphorylates BMPRI, activating its kinase activity. 
Then, type I receptors phosphorylate SMAD proteins.  In response to BMP4, SMAD-1, 5, 
and 8 proteins (also known as receptor-smad or R-smad) are phosphorylated, while TGFβ 
phosphorylates SMAD-2 and –3.  Upon phosphorylation, SMAD-1 associates with 
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SMAD-4 (co-smad) and the complex translocates to the nucleus where it can regulate 
transcription factors or bind directly to DNA 75 to regulate gene expression.  SMAD-6 
and –7 are inhibitory proteins, competing with SMAD-1, -5 and -8 and blocking BMP 
signaling.  Interestingly, it has been shown that LS induces the expression of two 
inhibitory signaling molecules, SMAD-6 and -7 76 , providing an additional mechanism 
by which LS prevents BMP4-dependent responses.  
 
Figure 1.2. BMP receptors and signalling cascades. BMPs bind to BMP receptor type I 
and type II, then initiate intracellular signaling pathways. This figure is taken from the 
paper of Yamashita et al 77.  
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While the Smad pathway is the well-characterized canonical signaling mechanism 
for BMPs, other pathways involving MAPK and NFκb 17,78 have also been shown to be 
BMP-inducible. Several groups have found that BMP4 treatment increased 
phosphorylation of MAPK such as ERK 1/2, p38 and JNK in various cell types 79,80. The 
specific pathway activated by BMP4 may depend on the BMP receptor oligomerization 
pattern. Knaus’ group suggested that preformed type I/ type II heterodimers activate the 
Smad pathway by ligand, whereas nascent formation of hetero-dimers of type I and type 
II complex upon ligand binding stimulates the p38 pathway 81,82. Also, MAPK activation 
by BMP may act as a negative feedback mechanism for the Smad pathway by acting as 
an inhibitor of Smad1 nuclear translocation. It has been shown  that phosphorylated ERK 
1/2 binds to the linker domain of Smad1, which inhibits its binding to Smad4, thereby 
inhibiting its translocation into the nucleus 83. 
 
Overall Hypothesis 
Based on studies from literature and our lab’s previous work, we constructed 
several specific aims over several years during PhD training. 
In the beginning of this work, we have studied the mechanisms by which OS 
stimulates inflammatory responses and atherosclerosis.  Using a cone-and-plate shear 
apparatus, we have shown that OS increases monocyte adhesion in vitro in a BMP4-
dependent manner. OS induces BMP4 production, which leads an inflammatory response 
in endothelial cells 17. The expression of adhesion molecules on the endothelial cell 
surface then allows monocytes to adhere to the endothelium 17. The detailed mechanisms 
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mediating OS and BMP4-induced monocyte adhesion at the BMP receptor level is the 
subject of this dissertation project.  
 
Oscillatory shear (OS)
Monocyte-adhesion
Foam cell
formation
Induces BMP4
Atherosclerosis
ICAM-1
NFκB
BMP4 inhibitor
(noggin, 
Follisatatin, 
siRNA)
Laminar  shear (LS)
Inhibits VCAM-1
OS
LS
BMP 
receptor?
 
Figure 1.3 Summary of previous study. BMP4 produced by OS induces monocyte 
adhesion. BMP4 antagonists, noggin and follistatin or BMP4 siRNA can block this 
pathway. For this dissertation, we investigated a role of BMP receptors to induce 
monocyte adhesion. 
 
Hypothesis: Oscillatory shear stress increases BMP4, which promotes monocyte 
adhesion and leads to atherosclerosis in branched arteries. This action is mediated by 
BMP receptors expressed in endothelial cells, with each receptor playing a unique role. 
Therefore, we set out to investigate a role for BMP receptors and downstream signaling 
of BMP4 in inflammation in endothelial cells. Unexpectedly, we found that knockdown 
of BMPRII increases inflammation independent of BMP4. Therefore, we hypothesize 
that BMPRII is a critical regulator of inflammation in endothelial cells and 
atherosclerosis. 
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Specific Aim 1:  Characterize endothelial BMP receptor expression in endothelial cells. 
Hypothesis: It has been shown that different cell types and origins express different BMP 
receptor subtypes. Therefore, we hypothesized that endothelial cells express certain BMP 
receptors and the localization of each BMP receptor is important to its function and 
mediation of inflammation in response to OS-produced BMP4. This aim will be 
discussed in chapter 2. 
 
Specific Aim 2: Identify a function for BMPRII and investigate downstream pathways 
mediating inflammation in endothelial cells. 
Hypothesis: We first hypothesized that BMPRII mediates BMP4-induced inflammatory 
responses. Using a BMP receptors siRNA knockdown approach, we investigated 
functions of BMP receptors inducing BMP4-dependent and independent inflammation. 
Unexpectedly, we discovered that BMPRII knockdown increased monocyte adhesion in 
dependent of BMP4. Therefore, we modified our hypothesis which BMPRII depletion 
increases inflammatory responses. Also we investigated the downstream signaling 
pathways including ROS and NFκB pathways. This aim will be discussed in chapter 3. 
 
Specific Aim 3:  Investigate the regulation of BMPRII expression in endothelial cells.  
Hypothesis: Recently, mutations of BMPRII have been associated with primary 
pulmonary hypertension. Also it has been shown that familial and sporadic cases of 
pulmonary hypertension patients decreased BMPRII expression in lungs. However, there 
has been no study to investigate BMPRII expression in atherosclerosis. Therefore, we 
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hypothesized that endothelial BMPRII expression varies according to the state of 
atherosclerotic plaque development.  In addition, pro-atherogenic factors such as 
cytokines, hyperlipidimea, hypertension, and diabetes, or anti-atherogenic factors, such as 
lipid lowering and anti-inflammatory drugs, regulate BMPRII expression conversely in 
endothelial cells. This aim will be discussed in chapter 4 and 5. 
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Chapter 2 
 
Characterization of BMP receptors in endothelial cells. 
 
 
Introduction 
 
 
BMPs bind to two types of BMP-specific receptors (Type I and Type II);  there 
are BMPRI (ALK2, ALK3, ALK6) and BMPRII. When BMPs bind to BMPRII, BMPRII 
forms a hetero-dimer with BMPRI, phosphorylating it. Then, BMPRI phosphorylates 
Smad 1/5/8 proteins, which bind with Smad 4. This Smad complex translocates to the 
nucleus and binds to DNA to regulate gene expression (Figure 2.1). Inhibitory Smad 6 
and 7 proteins can block this pathway. Smad 6 has been shown to preferentially 
inhibiting the BMP pathways by inhibiting phosphorylation of Smad 1 and preventing 
Smad 4 binding. In contrast, Smad 7 is a more general inhibitor of the TGF-β family. It 
binds to type I receptors to inhibit phosphorylation of Smad 1/5/8 1,2. 
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Figure 2.1. BMPs bind to BMP receptors to activate Smad signaling pathways 1. 
BMPs bind to BMP receptors: BMPRII phosphorylates BMPRI, which phosphorylates 
Smad 1/5. Smad 1/5 phosphorylation can be inhibited by Smad 6/7, or phosphorylated 
Smad 1/5 can bind to Smad4 and translocate to nucleus. Smad proteins are transcription 
factors that involves in regulating several genes in response to the stimulus. 
 
 
Each BMP family member binds to a different combination of BMP receptors. 
Table 1 summarizes BMP receptor oligomerization patterns by BMP2, BMP4 and BMP7 
from literature. There are reports that BMP2 and BMP7 can bind to ALK2. In contrast, 
BMP4 has a weak binding affinity for ALK2 (personal communication with Peter ten 
Dijke), but has shown to bind to BMP type I receptors, ALK3 and ALK6. In contrast to 
TGF-β receptors, which were found to be fully homo-dimeric in the absence of ligand, 
BMP receptors can make homo-dimers and hetero-dimers in the presence and absence of 
ligand. It also seems that each cell types express and form different types of BMP 
receptor dimers. 
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Table 2.1.  Each type of BMP ligand binds different combinations of receptors in 
different cell types. (COS-1: monkey kidney fibroblast, P19: mouse teratocarcinoma 
cells, MC3T3: mouse embryonic fibroblast, AG1518: human foreskin fibroblast, 
NIH3T3: mouse fibroblast cell line, MvILu: mink lung cells) 
 
Ligand Type I Type II Cell Type Reference
ALK2, ALK3,  ALK6 BMPRII COS 3 
BMP2 
ALK3, ALK6 
BMPRII 
ActRII a, b 
P19 4 
ALK 3, ALK6 BMPRII COS, MC3T3, AG1518 5 
BMP4 
Not binding to ALK2 BMPRII NIH 3T3 6 
BMP7 ALK2, ALK3, ALK6 BMPRII COS, MC3T3, MvILu, 4,5 
 
 
Aortic endothelial cells have been shown to express both BMP receptor type I and 
II 7. However, there is evidence that vascular cells of different origin express different 
types of receptors. For example, human pulmonary arterial endothelial cells express 
ALK6, not ALK3, while pulmonary smooth muscle cells express both ALK3 and ALK6 8. 
Table 2 summarizes the differential expression of BMP receptors in various cell types. 
This indicates that the specific combination of BMPRs may play an important role in 
each cell types. 
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Table 2.2. Different cell types express different combinations of BMP receptors. 
(MEEC: Mouse Embryonic Endothelial Cells, HPAEC: Human Pulmonary Aortic 
Endothelial cells, MPASM: Mouse Pulmonary Aortic Smooth Muscle cells, HASM: 
Human Aortic Smooth Muscle cells, RASM: Rat Aortic Smooth Muscle cells, HPASM: 
Human Pulmonary Aortic Smooth Muscle cells, MEF: Mouse Embryonic Fibroblasts, 
KS483: mouse pre osteoblast, O: expressed, ×: not expressed, -: not examined)  
 
 
 
To elucidate the importance of BMPRs in cardiovascular pathology, we screened 
BMP receptor expression in various endothelial cells, including cultured BAEC, HUVEC, 
and HAEC, as well as mouse aortas, and human coronary arteries. To evaluate receptor 
expression, we used RT-PCR, Western blot, and immunostating to evaluate mRNA and 
protein expression of BMPR type I (ALK2, ALK3, and ALK6) and BMPRII.  
   
 
 
 
 
 
 
137512865777Ref.
PCRPCRPCRPCRPCRPCRPCRPCRPCRIHCMethod
ooo-×oooooBMPRII
o×ooo-oo×oALK6
oooooo××ooALK3
oooo×oooo×ALK2
KS483MEFHPASMRASMHASMMPASMHPAECBAECMEEC
Mouse 
aorta 
(EC)
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Methods 
 
Cell culture: HUVECs, purchased from the Department of Dermatology, Emory 
University, were cultured in M-199 medium supplemented with endothelial growth factor 
supplement (isolated by us), heparin (American Pharmaceutical Partners), and 20% heat 
inactivated fetal bovine serum (FBS, Atlanta Biolicals), and used between passages 3-6.  
BAECs, obtained from Cell Applications Inc., were maintained in a standard humidified 
incubator (37°C, 5% CO2) in Dulbecco’s minimum Eagle’s medium (Gibco) 
supplemented with 10% FBS, heparin, endothelial cell growth supplement and minimum 
nonessential amino acids (Gibco). BAEC from passage 8-11 were used. HAECs 
purchased from Clonetics were cultured using the EGM-2 bullet kit (Clonetics) and used 
at passages 4–6.  
 
 
RT-PCR: RT-PCR for ALK2, ALK3, ALK6 and BMPRII mRNA was performed using a 
BioRad MyCycler (Bio-Rad). Briefly, total RNA was reverse transcribed using random 
primers and a SuperscriptII kit (Invitrogen) to synthesize first-strand cDNA. The cDNA 
was purified using a MicroBiospin 30 column (Bio-Rad) in Tris buffer and stored at          
-20°C until used. Aliquots of the cDNA pool obtained were subjected to PCR and 
amplified in a 50 µl reaction mixture using Taq polymerase (Invitrogen) for 45 cycles.  
Reaction products were separated on a 1% agarose gel, and the amplified DNA fragments 
were visualized by ethidium bromide staining under UV light.  PCR products were 
sequenced to confirm the intended product.  The following primers were used to amplify 
human ALK2 (forward, 5-gcggtaatgaggaccactgt -3, reverse, 5-agaccagagccacttcctga -3), 
bovine ALK2 (forward, 5- ccccgaagttcttgatgaaa -3, reverse, 5-ctgtgagtctggcagatgga-3), 
human ALK3 (forward, 5-actttagcaccagaggatacc-3, reverse,  5-ttttcaccacgccatttaccc-3), 
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bovine ALK3 (forward, 5-ctacactgccccctgttgtt actttagcaccagaggatacc-3, reverse,  5-
cgcattagcgcagtttgata-3), human ALK6 (forward, 5-caccctacactgcctccatt -3, reverse, 5-
acttccccatagcgaccttt -3), bovine ALK6 (forward, 5-tatagctgacctgggcttgg-3, reverse, 5-
ccgcagcttcttgatacaca -3),human BMPRII (forward,  5- gacaacattgcccgctttat -3, reverse, 5- 
atctcgatgggaaattgcag -3), and bovine BMPRII (forward,  5- gaagactgttgggaccagga -3, 
reverse, 5- ctggacatcgaatgctcaga -3).  
 
Western blot: Following experimental treatments, endothelial cell lysates were prepared 
and analyzed by Western blot analysis as previously described9,10. Briefly, cells were 
washed in ice-cold phosphate-buffered saline and lysed in RIPA buffer, and protein 
concentrations were determined with a Bio-Rad DC assay. Aliquots of cell lysates were 
resolved via SDS-PAGE and transferred to a polyvinylidene difluoride membrane 
(Millipore). The membranes were probed with antibodies to ALK2 (1:1000, R&D), 
ALK3 (1:500, Santa Cruz), ALK6 (1:500, Santa Cruz), BMPRII (1:500, BD), ICAM-1 
(1:1000, Santa Cruz), VCAM-1 (1:1000, Santa Cruz), or β-actin (1:1000, Santa Cruz), 
and with appropriate secondary antibodies conjugated to alkaline phosphatase. Protein 
bands were detected by a chemiluminescence method. To confirm the specificity of the 
antibody, we also used blocking peptide for ALK3 and ALK6 by incubating with primary 
antibodies, respectively.  
 
Immunostaining: For immunohistochemical staining, frozen sections of human coronary 
arteries (10 µm) and mouse aortas (7 µm) were fixed in ice-cold acetone for 5 min, 
blocked for 1 hour with 10% donkey or goat serum and incubated with primary 
antibodies overnight at 4°C. Samples were then incubated with rhodamine-conjugated 
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secondary antibodies (anti-goat IgG or anti-rat IgG) for 2 hours at room temperature, as 
described 10. Nuclei were counter-stained with Hoechst 33258 (Sigma). Primary 
antibodies used were specific for ALK3 (1:50, Santa Cruz), ALK6 (1:50, Santa Cruz), 
BMPRII (1:50, Santa Cruz) or PECAM-1 (1:50, BD). Twenty different human coronary 
arteries were examined. Samples ranged from minimally diseased to those with advanced 
atheromas. Microscopic images were collected using a Zeiss epi-fluorescent microscope. 
For immunocytochemistry, confluent BEC were fixed with 4% paraformaldehyde, 
permeabilized with 0.2% Triton X-100, and blocked for 1hr with 3% bovine serum 
albumin. Cells were incubated with primary and secondary antibodies and observed via 
confocal microscopy (Axiovert, Zeiss),  as we previously described 11.  
 
Statistical Analysis: Data are reported as average ± SEM obtained from at least 3 
independent studies. Statistical significance was assessed by Student’s t-test. P<0.05 was 
considered as statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33
Results 
 
 
HAEC, HUVEC, and BAEC express ALK2, ALK3, ALK6, and BMPRII mRNA, 
but only ALK2, ALK6, and BMPRII proteins. 
 
 
Figure 2.2. HAEC, HUVEC, and BAEC express ALK2, ALK3, ALK6, and BMPRII 
mRNA, but only ALK2, ALK6, and BMPRII proteins. The expression of BMP 
receptors was determined by RT-PCR (A), Western blot (B) (A) RT-PCR reactions for 
ALK2, 3, 6 and BMPRII were carried out using HAEC, HUVEC and BAEC. Each 
product was resolved by 1% agarose gel electrophoresis. (B) Lysates of mouse lung, 
HAEC, HUVEC, and BAEC were analyzed by immunoblot with antibodies to ALK2, 3 
and 6, and BMPRII. β-actin was used as a loading control. (C) Lysates of mouse heart 
and lung were analyzed by immunoblot using antibodies to ALK3, and ALK6. For (+) 
antigen cases, antibodies were incubated with blocking peptides prior to incubation with 
blots. 
 
HAEC, HUVEC, and BAEC expressed ALK2, ALK3, ALK6, and BMPRII 
mRNA as shown in Figure 2.2 (A). However, Western blots showed that HAEC, 
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HUVEC, and BAEC expressed only ALK2, ALK6, and BMPRII at the protein level. 
ALK3 was not detected. In comparison, mouse lung expressed ALK2, ALK3, ALK6 and 
BMPRII proteins (Fig. 2.2 (B)), while mouse heart expressed ALK2 and ALK3, but not 
ALK6 and BMPRII proteins (Fig.2.2 (C)).  The specificity of antibodies for ALK3 and 
ALK6 was confirmed by competing with excess amounts of blocking peptide (Fig. 2.2 
(D)).  In these studies, we observed that the molecular weight of BMPRII varied between 
cell types. Mouse lung and HAEC expressed protein both at 140 and 120kDa, while 
HUVEC expressed only a 120kDa protein and BAEC only a140kDa protein. Cultured 
endothelial cells expressed all three isoforms of BMPRI (ALK2, ALK3, and ALK6) 
mRNA; however, ALK3 protein was undetectable.  
 
Mouse endothelium expresses ALK6 and BMPRII. 
 
Using immunohistochemical staining, we next examined BMP receptor 
expression in ECs from mouse aortas and human coronary arteries by.  As shown in Fig. 
2.3, BMPRII, but not ALK3 were easily detectable in ECs.  In addition, a low level of 
staining for ALK6 was detected at the basal layer of ECs, as indicated by the faint pink 
staining just above the internal elastic lamina (marked with arrows in Fig. 2.3 (C)). 
PECAM-1 antibody (Fig. 2.3 (D)) confirmed the presence of an intact endothelial layer in 
all sections. Unlike endothelium, medial smooth muscle cells robustly expressed ALK3, 
ALK6 and BMPRII (Fig. 2.3).  We were not able to find antibodies that were adequate 
for ALK2 staining with mouse aortas (data not shown). These data confirms that in situ 
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investigation of endothelial cells as well as cultured endothelial cells express ALK6 and 
BMPRII not ALK3.  
 
 
Figure 2.3. Mouse endothelium expresses ALK6 and BMPRII. Frozen sections of 
mouse thoracic aortas were stained with specific antibodies: ALK3, ALK6, BMPRII, and 
PECAM-1. Non-immune IgG control (non-IgG) was used as a control. Each antibody 
was detected with rhodamine-conjugated secondary antibodies (red signal) and observed 
by fluorescence microscopy (original magnification is 400x). Blue indicates nuclei 
stained with Hoechst while green signal indicates elastic lamina detected by auto 
fluorescence. L indicates the vessel lumen and arrows point to ECs.  
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Endothelial cells in human coronary arteries express ALK2, ALK6 and BMPRII. 
 
 
 
Figure 2.4. Endothelial cells in human coronary arteries express ALK2, ALK6 and 
BMPRII. Frozen sections of human coronary arteries were stained with specific 
antibodies: ALK2, ALK3, ALK6, BMPRII.  Non-immune IgG control (non-IgG) was 
used as a control. For F) BMPRII antibody was pre-incubated with BMPRII blocking 
peptide prior to antibody incubation. Each antibody was detected with rhodamine-
conjugated secondary antibodies (red signal) and observed by fluorescence microscopy 
(original magnification 100×). Blue indicates nuclei stained with Hoechst while green 
signal indicates elastic laminae detected by autofluorescence. L indicates the vessel 
lumen and arrows point to ECs.  
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To assess expression patterns in human samples, we also stained human coronary 
arteries for ALK2, ALK3, ALK6, and BMPRII. In human coronary arteries, we were able 
to detect ALK2 (Fig. 2.4 (A)) in both endothelium and smooth muscle cells.  In addition, 
ECs from human coronary arteries expressed ALK6, but not ALK3 (Figure 2.4 (B)) and 
(C)). Specificity of BMPRII staining was confirmed with incubating antibody by 
competition staining (Figure 2.4 (E) and (F)). The secondary antibody alone (Fig. 2.4 
(D)) was used as a staining control.   
 
Together, these results suggest that ALK2, ALK6, and BMPRII are expressed in 
both cultured ECs and in intact mouse and human aortas. In the case of ALK3, although 
we were able to detect mRNA in cultured endothelial cells, it is possible that protein 
expression maybe very low and beneath the detection level of the antibody used. Since 
we were able to detect stable expression of BMPRII  in both cultured endothelial cells 
and in situ mouse aortas and human coronary arteries, we have decided to focus on 
BMPRII  as our the first target of the further studies.  
 
 
BMPRII is expressed at the cell-cell junction in endothelial cells. 
 
 
 Our findings indicate that BMPRII expression is the most pronounced and 
consistent of BMPRs in both cultured endothelial cells and mouse aorta staining studies. 
As a result, we decided to further investigate BMPRII expression. We first carried out 
immunostaining studies to determine BMPRII expression in cultured BEC.  This work 
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indicated that BMPRII was mainly expressed in cell-cell junctions (Fig. 2.5 (A)-b).  To 
verify these finding, we co-stained confluent BEC for BMPRII and VE-cadherin, a 
marker of the cell-cell junction, together.  As shown in confocal images (Fig. 2.5 (A) (b-
d)), BMPRII co-localized with VE-cadherin in areas where cell-cell contact was 
maintained (marked with arrowheads), but not in those where the junctions were 
disrupted (marked with the arrows). To assess this pattern, we compared the BMPRII 
staining pattern in confluent BEC to sub-confluent BEC without formed junctions. Sub-
confluent BEC did not exhibit the junctional staining pattern for BMPRII (Fig. 2.5 (A) a).  
In addition, when confluent BEC were scratched (marked as “sc”) to remove junctions on 
one side of the cell monolayer and fixed two hours later, BECs lost the junctional 
BMPRII staining pattern on the scratched side (arrows in Fig. 2.5 (B) e-g). In contrast, 
unscratched areas maintained junctional staining (arrowheads in Fig. 2.5 (B) e-g). The 
junctional staining pattern of the BMPRII antibody was significantly and specifically 
reduced by peptide competition staining (compare e to h in Fig. 2.5).  In the absence of 
the blocking peptide, the merged image (Fig. 2.5.g) of BMPRII and VE-cadherin staining 
showed yellow staining at the junction, indicative of co-localization of the two. On the 
other hand, in the presence of the blocking peptide, the merged image (Fig. 2.5.j) showed 
only red VE-cadherin staining at the cell-cell junction, indicating specific loss of the 
BMPRII signal. These results demonstrate that BMPRII is expressed in the cell-cell 
junction in EC. In HUVECs, we have not been able to show the immunostaining because 
of the technical problems that HUVECs were very hard to keep an undisrupted cell 
monolayer during the staining procedure. 
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Figure 2.5. BMPRII is expressed at the cell-cell junction in endothelial cells. (A) Sub-
confluent (a) or confluent (b-d) BEC were co-stained with antibodies to BMPRII (green 
stain) and VE-cadherin (red stain).  In (B), confluent EC were scratched to remove the 
junction (as indicated by sc), then stained with BMPRII and VE-cadherin antibodies in 
the absence (-) or presence (+) of the antigenic peptides, demonstrating the specificity of 
the BMPRII antibody staining. Yellow staining in the merged images (d, g, j) indicates 
the co-localization of BMPRII and VE-cadherin. Confocal images (400x) are 
representatives of three independent studies. Arrowheads and arrows indicate intact and 
disrupted junctions, respectively. 
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BMPRII expression is not affected by shear stress. 
 
 
 
 
Figure 2.6. BMPRII expression is not affected by shear stress. (A) and (B) Confluent 
BEC and HUVECs were exposed to OS, LS, or static conditions for 24 hours. Cell 
lysates were collected, and equal amount of protein were assessed by Western blot. Blots 
were probed with BMPRIII antibodies. β-actin was used as an internal control. Shown are 
mean ± SEM (n=3, * p<0.05) A) Confluent EC were fixed with 4% paraformaldehyde 
after shear exposure, and stained with BMPRII antibody. Confocal images (400x) are 
representative of three independent studies. 
 
It has been shown that several junctional proteins, such as PECAM-1, VE-
Cadherin, or VEGF-R, suggested as a mechonasensor in endothelial cells. Since BMPRII 
exhibited the junctional staining pattern, we investigated whether BMPRII was a 
mechnosensitive protein or now. Therefore, we first examined whether BMPRII 
expression was regulated by shear stress. EC and HUVEC were exposed to ST, LS, and 
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OS for 24 hours. BMPRII expression did not appear to be shear-sensitive with 24 hour 
shear exposure. Both EC and HUVECs showed no change in protein level as analyzed by 
Western blot (Fig. 2.6 (A) and (B)). Also, there was no difference in the staining intensity 
of BMPRII after 24 hr shear exposure to LS versus OS (Fig 2.6 (A)). These data indicate 
that 24 hour shear exposure to both LS and OS does not affect either BMPRII protein 
expression or localization; however, it is still possible that different types of shear stress 
would change other junctional proteins which interact with BMPRII at the cell-cell 
junction.  
 
Discussion 
  
 The major findings reported in this study are that a) HAEC, HUVEC, and BAEC 
express ALK2, ALK3, ALK6, and BMPRII mRNA. b) ALK2, ALK3, and BMPRII 
proteins were detected in HAEC, HUVEC, BAEC, mouse aortic ECs, and human 
coronary arterial ECs. c) BMPRII is expressed at the cell-cell junction in EC; and d) 
Shear stress does not affect the expression of BMPRII in EC or HUVECs. Together, 
these findings suggest that endothelial cells express both type I and type II receptors of 
BMPs which indicate that these cells can be stimulated by BMP signals.  
 
There have been studies on BMP receptors in both biochemical studies and 
pathophysiological studies. BMP receptors have been identified and sequenced to 
determine sizes of proteins: For BMP type I recpetors, ALK2 is a 509 amino acid protein, 
ALK3 is a 532 amino acid protein, and ALK6 is a 502 amino acid protein. BMPRII is a 
1038 amino acid protein with a long cytosolic tail (866 amino acid) with poorly defined 
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function.  Also, in terms of pathophysiological studies, mutations in ALK6 are known to 
cause brachydactyly type A2, which results in shortness of the fingers and toes 21. ALK2 
conditional knock out mice in neural crest cells display a cardiac outflow tract defect 22. 
Recently, heterozygous germline BMPRII mutations have been found to underlie many 
cases of familial and sporadic primary pulmonary hypertension 23. The disease is 
characterized by vascular cell proliferation and obliteration of the small pulmonary 
arteries.   
 
We detected mRNA of all types of BMPRs (ALK2, ALK3, ALK6 and BMPR2) 
that we investigated in endothelial cells. We also detected proteins of ALK2, ALK6 and 
BMPRII; however, ALK3 protein level was under our detection limits in endothelial cells. 
Interestingly, we detected two different sizes of BMPRII using Western blot. In mouse 
lung and HAEC, both 120kDa and 140kDa band were detected. In HUVEC, only 120kDa 
band was detected, and in BAEC, only a 140kDa band was detected. This suggests that 
aortic cells express a different isoform of BMPRII than venous cells. Further studies will 
be necessary to confirm these findings. Using other cell types such as human pulmonary 
arterial and venous endothelial cells, we may be able to determine whether origin or 
species dictates BMPRII size. In addition, we may also study whether different splice 
variants exist, and what would affect the transcription of each variant. It is possible that 
there is a difference in glycosylation. Finally, functional and localizational studies of each 
variant would need to be performed in endothelial cells.  
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Our immunostaining study showed for the first time that BMPRII is expressed in 
the cell-cell junction of EC (Fig.2.4).  To confirm its location and the antibody’s 
specificity, several independent approaches were used:  1) comparison between confluent 
vs. sub-confluent or scratched ECs, 2) co-localization of VE-cadherin and BMPRII, 3) an 
antigenic peptide competition study with the BMPRII antibody, and 4) the specific loss of 
BMPRII signal by BMPRII siRNA but not by non-silencing siRNA (data not shown). 
Previously, Ramos et al. showed that some BMPRII (less than 6% of total) are located in 
lipid rafts, including caveolae, in human pulmonary arterial ECs (HPAEC) 9. It is 
possible that some BMPRII may be located in caveolae in our cells, but this was not 
addressed here.  Given the importance of the cell-cell junction in mechanosensing and 
mechanosignaling in ECs 25-27, BMPRII localization in the junction is interesting. A 
recent study reported that BMP induces nuclear localization of β-catenin mediated by 
adherence junction formation in chondrogenesis 28. This finding and our finding that 
BMPRII is primarily located in the cell-cell junction raises the possibility that BMP 
action may be mediated through the cell-cell junction complex. Also junctional proteins 
such as VE-cadherin and PECAM-1 are known to be mechanically sensitive to fluid 
shear stress. For PECAM-1, onset of steady shear stress result in a rapid c-src dependent 
tyrosine phosphorylation of PECAM-1 and recruitment of SHP2 (a tyrosine 
phosphatase); also, ERK 1/2 activation is dependent on this PECAM-1/SHP2 activation 
25,29. As for VE-cadherin, the onset of steady flow triggers an immediate and transient 
increase in β-catenin and flk-1 (VEGFR2) association with VE-cadherin that decreases 
after 5 min of exposure and results in the activation of Akt 26. Even though we have not 
seen any differences in BMPRII expression by shear stress, these findings indicate that 
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shear stress may change the composition of junctional complexes with BMPRII as a 
modulator.   
Intercellular junction proteins regulate cell layer permeability, retard cell 
migration, maintain cellular integrity, and transfer intracellular signals. These proteins are 
recognized as possible mechanosensors because of their specific location in the cell.  
They can transfer information intracellularly by interacting with the cytoskeleton via 
several anchoring molecules 10. Vascular Endothelial cadherin (VE-cadherin) and 
PECAM-1 are the two most well known junction proteins.  VE-cadherin forms a 
junctional complex with armadillo family members including α, β, and γ-catenin, p120, 
Plakoglobin, and actin filament 11-14, and PECAM-1 with β and γ-catenin. Each of these 
proteins is involved in maintaining integrity and stabilization of the junction, or signaling 
via transcriptional activity 15,16. Furthermore, Luscinskas’ group has reported that the VE-
cadherin complex may play an important role in the migration of circulating leukocytes 
under flow conditions 17. This information suggested to us that BMPRII could also be 
involved in monocyte migration through the intercellular junction, in addition to BMP4- 
induced monocyte adhesion.  
 
In summary, endothelial cells express both BMP type I receptors and type II 
receptors, and BMPRII could potentially be important in inflammation and monocyte 
infiltration mediated by endothelial cells.  
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Chapter 3 
 
BMPRII is a critical regulator of inflammation in endothelial cells. 
 
Introduction 
  
 Atherosclerosis is known as an inflammatory disease 1,2, occurring preferentially 
in branched or curved arteries exposed to unstable flow conditions including low and 
oscillatory shear conditions (OS) 3-6. In contrast, the straight regions of the vasculature, 
which are exposed to relatively high levels of laminar shear stress (LS), are resistant to 
atherogenesis. Despite the well-known importance of these two different flow conditions, 
the underlying mechanisms for shear-induced atherogenesis are still unclear.  In an 
attempt to identify mechanosensitive genes that are differentially regulated by OS and LS, 
several groups including us have carried out transcript profiling studies 6-12.  Some of 
these mechanosensitive genes identified by this work are likely to play critical roles in 
mediating site-specific inflammation and atherosclerosis development. 
  
 Through these microarray studies, we identified bone morphogenic protein 4 
(BMP4) as a critical regulator of an inflammatory response.  We have discovered that 
BMP4 is produced in ECs in response to OS, but is blunted by LS 8,13. BMP4 stimulates 
inflammation via cell-surface expression of intercellular adhesion molecule-1 (ICAM-1) 
and monocyte adhesion to ECs, in an NF-κB- and NADPH oxidase-dependent manner 13-
15, as discussed in chapter 2.  More recently, we have shown that chronic infusion of 
BMP4 causes systemic hypertension by mechanisms involving activation of arterial 
NADPH oxidases and endothelial dysfunction in wild-type (C57BL/6) and ApoE-
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deficient mice, but not in those mice lacking the p47phox component of the NADPH 
oxidase 16.  However, the detailed signaling mechanisms mediating the BMP4 effects are 
still not known. The aim of the study is to determine the underlying mechanisms.  
 
 BMP actions are mediated by two different types of the BMP receptors (BMPR): 
Type I receptors (ALK2, ALK3, and ALK6) and Type II receptors (BMPRII, ActRII and 
Act-RIIb) 17. Upon binding to BMPs, Type I BMPRs are activated by BMPRII and 
phosphorylate smad-1/5/8 proteins which form a complex with co-smad (Smad 4). The 
smad complexes then translocate to the nucleus and regulate BMP-specific gene 
expression such as inhibitor of diffentiation-1 (id-1)18,19. Recently, loss-of-function 
mutations of BMPRII have been linked to primary pulmonary hypertension (PPH) in 
humans20, demonstrating its importance in pulmonary arterial biology and 
pathophysiology.  However, it is not known whether BMPRs play a critical role in 
pathophysiology of the non-pulmonary vasculature. Especially the conduit of vascular 
endothelial cells in regulation of the inflammation and atherosclerosis will be the focus of 
this study.  
 
 Here, we examined the hypothesis that BMP4 induces inflammatory responses in 
ECs in a BMP receptor-dependent manner. To test this hypothesis, we first characterized 
BMP receptor mRNA and protein expression in cultured ECs and in mouse aortas, as 
discussed in chapter 3. Based on those results, we then examined the effect of BMPRII 
depletion on monocyte adhesion in control and BMP4-treated ECs. These results showed 
that BMPRII gene silencing inhibited BMP4-induced inflammation. Surprisingly, the 
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knockdown of BMPRII itself induced inflammatory responses in the absence of BMP 
ligands. These findings uncovered BMPRII’s constitutive role as a potential repressor of 
inflammation in ECs. Therefore, we hypothesized that down-regulation of BMPRII 
increases inflammation in endothelial cells. Subsequent studies focused on the 
identification of down-stream signaling pathways including ROS, mitogen activated 
protein kinase (MAPK), NFκB, and ICAM-1.  
 
Methods 
 
Cell culture and siRNA transfection: HUVEC purchased from Emory University were 
cultured in M-199 supplemented with endothelial growth factor supplement, heparin, and 
20% fetal bovine serum (FBS), and used between passages 3-6.  HUVEC were 
transfected with human BMPRII siRNA (5’-
UGAACGCAACCUGUCACAUAAUAGGCG-3’ from MWG Biotech) duplexes with 
100 nM concentrations using Oligofectamine (Invitrogen) in serum-free media. After 6 
hrs, the media were supplemented to raise FBS concentration to 10%. Two days post-
transfection, the cells were exposed to rh-BMP4 (R&D) for 24 hrs in serum-free medium. 
BMPRII knockdown was confirmed by Western blot analysis using cell lysates.    
 
Western blot: Following treatments, endothelial cell lysates were prepared and analyzed 
by Western blot analysis as described by us 13,21. Briefly, cells were washed in ice-cold 
phosphate-buffered saline, lysed in RIPA buffer, and protein concentration determined 
with a Bio-Rad DC assay. Aliquots of cell lysates were resolved on a SDS-PAGE gel and 
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transferred to a polyvinylidene difluoride membrane (Millipore). The membranes were 
probed with antibodies to BMPRII (1:1000, BD), ICAM-1 (1:1000, Santa Cruz), VCAM-
1 (1:1000, Santa Cruz), phospho-Smad 1, 5, 8 (1:1000, cell signaling), total Smad 1,5,8 
(1:1000, Santa Cruz), phospho and total p38 (1:1000, cell signaling), phospho and total 
IκBα (1:1000, cell signaling)  or β-actin (1:1000, Santa Cruz), and appropriate secondary 
antibodies conjugated to alkaline phosphatase, which were detected by a 
chemiluminescence method.  
 
Monocyte binding: Following BMPRII siRNA transfection for two days and BMP4 
treatment for either 6hrs or 24hrs in HUVECs, the number of fluorescently labeled THP-
1 monocytes bound to endothelial cells after a 45 min incubation period under static 
condition was determined microscopically as described previously 13,22,23. In some studies 
of HUVECs, apocynin or an NFκB inhibitor, BAY 11-7082 were treated for two days 
after 6hr of transfection of BMPRII or non-silencing siRNA. 
 
Amplex-Red assay: Using a horseradish peroxidase-linked Amplex Red fluorescence 
assay, extracellular H2O2 was measured.  Briefly, after cells were transfected with non-
silencing or BMPRII siRNA, media were washed twice with Krebs Ringer Phosphate 
(KRP) buffer and incubated with 5 µM Amplex UltraRed (Molecular Probes) and 0.1 
U/ml horseradish peroxidase type II (Sigma-Aldrich) in KRP for 40 minutes.  Triplicate 
reading were taken in a 96-well plate using 100 µl samples of media, and fluorescence 
was detected via plate reader at excitation and emission of 530 nm and 580 nm, 
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respectively.  Hydrogen peroxide levels were normalized to cellular protein as measured 
by the Bio-Rad DC assay.   
 
Statistical Analysis: Data are reported as average ± SEM obtained from at least 3 
independent studies. Statistical significance was assessed by Student’s t-test. P<0.05 was 
considered as statistically significant. 
 
Results 
 We have shown previously that treatment of ECs with BMP4 stimulates 
monocyte adhesion to ECs 14, but it was not clear which BMP receptors mediated the 
inflammatory response. To examine whether BMPRII mediates BMP4-dependent 
monocyte adhesion in ECs, the cells were treated with siRNA to knockdown BMPRII 
expression, and then monocyte adhesion was determined. Prior to monocyte adhesion 
experiments, we investigated Smad 1/5/8 phosphorylation by BMP4 treatment in the 
presence of BMPRII siRNA (Fig 3.1.A) 
 
BMPRII knockdown blocks BMP4 induced Smad 1/5/8 phosphorylation. 
Transfection of HUVEC with 100nM BMPRII significantly reduced BMPRII 
proteins in Figure 4.1.b. We then tested the functional significance of the BMPRII 
knockdown by examining a canonical BMP4 signaling pathway, smad1/5/8 
phosphorylation.  As expected, BMP4 acutely (30 min and 60 min) stimulated smad1/5/8 
phosphorylation in HUVEC treated with the non-silencing siRNA control (Fig. 3.1 (B)). 
In contrast, BMPRII knockdown prevented smad 1/5/8 phosphorylation in response to 
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BMP4 (Fig. 3.1 (B)), supporting the expected notion that BMP4 stimulates smad1/5/8 
phosphorylation after binding to BMP receptors.  
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Figure 3.1. BMPRII knockdown blocks BMP4 induced Smad 1/5/8 phosphorylation. 
(A) A diagram of BMP4 signaling pathway through BMP receptors (RI: BMP type I 
receptor, RII: BMP type II receptor). (B) Sub-confluent HUVECs were transfected with 
BMPRII siRNA (BRII.si, 100 nM) or non-silencing RNA (Non.si, 100nM) for 48 hours. 
Transfected cells were then treated with BMP4 (100 ng/ml) upto 60 minutes.  BMPRII 
protein knockdown by siRNA was confirmed by Western blot. Cell lysates were 
collected and probed with antibodies to BMPRII, phospho-Smad 1/5/8, and total Smad 
1/5/8a, β actin antibody as an internal control. Shown are mean ± SEM, and phospho-
smad 1/5/8 signal was normalized to actin (*p<.05, n=3).  
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BMPRII knockdown stimulates inflammatory responses in basal cells.   
 We then carried out monocyte adhesion studies under the same conditions using 
the BMPRII siRNA and found a surprising result.  First, as expected, BMP4 increased 
monocyte adhesion by 200% above the vehicle control in non-silencing siRNA treated 
cells.  Unexpectedly, however, the BMPRII siRNA treatment of HUVEC significantly 
increased the monocyte adhesion response by 400% above the non-silencing vehicle 
control (Fig. 3.2 (B)). Moreover, BMP4 could no longer increase the monocyte adhesion 
response above that of the vehicle control in HUVEC treated with the BMPRII siRNA 
(Fig. 3.2 (B)).  However, in the TNFα treatment, BMPRII siRNA transfection increased 
monocyte adhesion above the non-silencing TNFα treatment suggesting that BMPRII 
siRNA transfection alone did not saturate inflammation inducing monocyte binding. We 
also investigated adhesion molecule expression by BMPRII knock down. As shown in 
Figure 3.2 (C), BMPRII knock down increased ICAM-1 protein level by 6-fold, and 
VCAM-1 level by 3-fold above that of non-silencing control (Fig 3.2 (C)). On the other 
hand, BMPRII knock down did not affect BMP4 protein level. These results suggest that 
BMPRII knock down itself is sufficient to stimulate inflammatory response including 
ICAM-1 and VCAM-1 induction and monocyte adhesion.   
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Figure 3.2. BMPRII knockdown stimulates inflammatory responses in basal cells.  
(A) A diagram of BMP4 signaling pathway through BMP receptors (RI: BMP type I 
receptor, RII: BMP type II receptor). (B and C) HUVECs were treated with 100 nM 
BMPRII siRNA (BRII.si) or non-silencing siRNA (Non.si) for 2 days. (B) siRNA treated 
HUVECs were exposed to BMP4 (100ng/ml) for 4 hrs followed by monocyte binding 
assay using THP-1 cells. Data shown is expressed as mean ± SEM (n=6, *p < 0.05).  (C) 
siRNA transfeced cells were lysed for immunoblot with antibodies to BMPRII, ICAM-1, 
and VCAM-1, using β-actin as loading controls. Data are expressed as mean ± SEM (n=4, 
*p < 0.05).    
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Knockdown of BMPRII increases inflammation through ROS dependent 
mechanism. 
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Figure 3.3. Knockdown of BMPRII increases inflammation through ROS dependent 
mechanism. A to C) HUVECs were treated with 100 nM BMPRII siRNA (BRII.si) or 
non-silencing siRNA (Non.si) for 2 days. B and C) Apocynin (60 µM) were treated with 
siRNA for 2 days. A) siRNA ± PEG-catalase treated HUVECs were analyzed using 
Amplex-Red assay to measure hydrogen peroxide. (*, p<0.05, n=4) B) siRNA ± 
Apocynin treated HUVECs were followed by monocyte binding assay using THP-1 cells. 
Data shown is expressed as mean ± SEM (n=6, *p < 0.05).  C) siRNA ± Apocynin 
transfeced cells were lysed for immunoblot with antibodies to BMPRII, and ICAM-1, 
using β-actin as loading controls. Data are expressed as mean ± SEM (n=4, *p < 0.05).    
 
Next, we hypothesized that BMPRII knock down induced inflammation is due to 
increase in ROS production. Therefore, we measured extracellular hydrogen peroxide 
(H2O2) level using Amplex-Red Assay. As shown in Fig. 3.3 (A), BMPRII knockdown 
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extracellular H2O2 by 50%. Cell permeable catalase (PEG-catalase) was used as a control. 
When HUVECs were pre-treated with PEG-catalase after non-silencing and BMPRII 
siRNA transfection, H2O2 production was blocked with BMPRII knockdown. To block 
ROS production, HUVECs were treated with apocynin, an NADPH inhibitor. Apocynin 
treatment blocked BMPRII knock down induced inflammation measured by monocyte 
binding (Fig. 3.3 (B)), and also ICAM-1 expression (Fig. 3.3 (C)).  
 
An NFκB inhibitor, BAY 11-7082, inhibits BMPRII knockdown induced 
inflammation. 
To look at involvement of NFκB signaling pathway, we used a pharmacological 
NFκB inhibitor, BAY 11-7082. It has been shown that BAY 11-7082 inhibits IκB 
phosphorylation, down-regulates IκB expression, and blocks NFκB translocation into 
nucleus. Also it blocks TNFα induced - ICAM-1, VCAM-1, and E-selectin expression in 
endothelial cells24. After transfection with non-silencing and BMPRII siRNA, HUVECs 
were treated with BAY 11-7082. Monocyte binding induced by BMPRII siRNA 
transfection was completely blocked (Fig 3.4 (A)) Also BAY 11-7082 treatment blocked 
ICAM-1 expression (Fig 3.4 (B)). We also looked IκB phosphorylation and IκB 
expression. As shown in Fig 3.4 B, BMPRII knock down increased IκB phosphorylation, 
and BAY 11-7082 blocked the phosphorylation. Expression of IκB was decreased by 
BMPRII siRNA transfection, however, BAY 11-7082 treatment did not increase IκB 
expression. Even though IκB expression was not increased by BAY 11-7082 treatment, 
the basal level of IκB was lower in BAY 11-7082 treatment compared to control, and 
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also IκB expression did not decrease further with BMPRII siRNA transfection in BAY 
11-7082 treatment.   
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Figure 3.4 An NFκB inhibitor, BAY 11-7082, inhibits BMPRII knockdown induced 
inflammation. (A) Pre-confluent HUVECs were transfeced with 100 nM of non-
silencing siRNA (Non.si) or BMPRII siRNA (BRII.si) for 2 days with or without Bay 11-
7082. monocyte binding assay was performed using THP-1 cells. Data shown is 
expressed as mean ± SEM (n=4, *p < 0.05). (B) siRNA ± Bay 11-7082 treated cells were 
lysed for immunoblot with antibodies to BMPRII, ICAM-1, phosphor-IκB, and total IκB, 
using β-actin as loading controls. Data are expressed as mean ± SEM (n=4, *p < 0.05).    
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BMPRII knockdown increases p38 phosphorylation in a basal level, but BMP4 
treatment decreases it.  
Phospho-p38
Total-p38
50
37
50
37
0
50
100
150
200
250
300
Non.si BRII.si
ph
os
ph
o-
p3
8 
(%
 c
on
tr
ol
)
0     30   60         0     30    60 (mim)
BMP4 
100ng/ml 0     30    60
Non.si BRII.si
(min)0    30    60
ph
os
ph
o-
p3
8 
(%
 c
on
tr
ol
)
 
Figure 3.5. BMPRII knockdown increases p38 phosphorylation in a basal level, but 
BMP4 treatment decreases it. Sub-confluent HUVECs were transfected with BMPRII 
siRNA (BRII.si, 100 nM) or non-silencing RNA (Non.si, 100nM) for 48 hours. 
Transfected cells were then treated with BMP4 (100 ng/ml) upto 60 minutes.  BMPRII 
protein knockdown by siRNA was confirmed by Western blot. Cell lysates were 
collected and probed with antibodies to phospho-p38, and total-p38, β actin antibody as 
an internal control. Shown are mean ± SEM, (*p<.05, n=3).  
 
As we discussed in introduction, it has been shown that cells that overexpressed 
with BMPRII mutant cDNA showed up-regulation of p38 phosphorylation25. Therefore, 
we also investigated p38 signaling pathway. BMPRII knockdown increased p38 
phosphorylation in the vehicle compared to non-silencing control, and also BMP4 
treatment decreased p38 phosphorylation in the BMPRII siRNA transfected HUVECs. 
Even though Smad 1/5/8 pathway was blocked by BMPRII knock down, p38 pathway 
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seems to be an extra signaling pathway when BMPRII expression is affected. This data 
suggests that activation of p38 pathway may be due to releasing upstream signaling 
molecues of the pathway by downregulating BMPRII expression.  
 
Discussion 
The major findings reported in this study are that a) knockdown of BMPRII 
blocks BMP4-dependent smad1/5/8 phosphorylation and monocyte adhesion.  
Unexpectedly, we found that b) BMPRII knockdown in HUVEC unleashes inflammatory 
responses in the absence of BMP4. Collectively, these findings show for the first time 
that a decrease in BMPRII protein level in aortic endothelium is linked to inflammation.   
In subsequent studies, we showed that c) BMPRII knockdown increases ICAM-1 and 
monocyte adhesion through ROS, and NFκB dependent pathways. 
  
Recently, heterozygous BMPRII mutations have been linked to familial and 
sporadic primary pulmonary hypertension (PPH) 20,26.  In addition, it has been reported 
that BMPRII expression is reduced in the lungs of the primary pulmonary hypertension 
patients even when they do not have any detectable mutations of the receptor 27. PPH is 
characterized by obliteration of pre-capillary pulmonary arteries, leading to sustained 
elevation of pulmonary arterial pressure and subsequent right ventricular hypertrophy. 
PPH is typically associated with abnormal proliferation of endothelial and smooth muscle 
cells within the small pulmonary arteries 28. Interestingly, PPH is also strongly associated 
with inflammation -as evidenced by accumulation of inflammatory cells infiltrating into 
the plexiform lesions in the lungs and increased inflammatory cytokines in the circulation 
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of the patients 29.  Homozygotic deletion of BMPRII in mice causes an embryonic lethal 
phenotype 30, while heterozygotic BMPRII+/- mice show increased susceptibility to 
pulmonary hypertension in response to an inflammatory stress 31. These results provide a 
link between BMPRII mutation or haplo-insufficiency and PPH as well as an association 
between inflammation and PPH.  However, there is no published literature showing that 
BMPRII mutation or decreased BMPRII expression causes inflammation and 
atherosclerosis.  
 
 As far as we are aware, this is the first report demonstrating that a decrease in 
BMPRII expression in ECs induces inflammation. Several lines of evidence support our 
conclusions: 1) We have shown that BMPRII siRNA increased monocyte adhesion, while 
non-silencing siRNA did not (Fig.3.2); 2) BMPRII knockdown increased ICAM-1 and 
VCMA-1 expression in ECs (Fig.3.2); 3) BMPRII knock down increased ROS 
production, and BMPRII knock down induced-inflammation was abolished with 
apocynin treatment (Fig. 3.3); and 4) Monocyte adhesion induced by BMPRII 
knockdown was blocked by an NFκB inhibitor and an ICAM-1 neutralizing antibody 
(YN-1) (Fig. 3. and Fig. 3.5).  
  
 The effects of BMPRII and BMPs seem to be cell type- and vascular bed- specific.  
Recently, BMPRII knockdown by siRNA was shown to increase apoptosis in human 
pulmonary aortic ECs 32. On the other hand, BMPRII knockdown in human pulmonary 
aortic smooth muscle cells (PASMC) inhibited apoptosis induced by BMP4/7 by 
mechanisms dependent on activation of caspases-3, 8 and 9 33.  However, these studies 
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did not examine whether BMPRII knockdown induces inflammation. Whether BMPRII 
knockdown causes apoptosis has not been examined in the current study, but BMP4 itself 
showed no significant effect on cell proliferation or apoptosis in “MAEC” and human 
aortic ECs (data not shown) previously in our lab.  Even within the same pulmonary 
arterial bed, smooth muscle cells from peripheral and proximal arteries respond 
differently.  BMP4 treatment increased proliferation of peripheral smooth muscle cells, 
but it inhibited that in proximal smooth muscle cells of pulmonary arteries 34.  
 
 The mechanism by which BMPRII knockdown stimulates ICAM-1 induction and 
subsequent monocyte adhesion in ECs is not known.  However, we propose that the loss 
of BMPRII may unleash the signaling proteins that normally bind to the receptor, 
resulting in uncontrolled activation of inflammatory pathways.  BMPRII is a protein 
(1,038 amino acids) with an extracellular BMP binding domain, a single transmembrane 
domain and a long cytoplasmic domain.  The cytoplasmic domain (866 amino acids) 
contains a serine/threonine protein kinase domain followed by a C-terminal tail.  
Interestingly, this long cytoplasmic domain is unique to BMPRII, and not found in other 
members of the TGFβ receptor superfamily.  Moreover, the cytoplasmic domain has been 
shown to bind various signaling proteins, cytoskeletal components and metabolic 
enzymes 35. Among notable ones are p50b NFκB protein, MAP3K8, LIM kinase-1 and c-
Src protein tyrosine kinase 35-37. For example, the C-terminal tail interacts with c-Src, and 
the association has been shown to downregulate the Src tyrosine kinase activity 37.  More 
interestingly, BMPRII mutations truncating the C-terminus, as found in PPH patients, 
increase c-Src activity and subsequent proliferation of smooth muscle cells 37.  Perhaps, 
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BMPRII, much like caveolins 38, serves as a docking protein in normal unstimulated 
conditions, holding the signaling proteins in an inactive state. When BMPRII level is 
decreased or its C-terminal is mutated or truncated as in the cases of PPH patients, the 
normally sequestered signaling proteins may be released and activated.  Similarly, when 
BMPRII is knocked down by siRNA, the signaling molecules that are normally 
sequestered by the receptor may be released and activated, leading to a vicious cycle of 
ICAM-1 induction, monocyte adhesion, and eventual atherosclerosis development. 
 
Also as shown in figure 3.6, BMPRII knock down by siRNA increased basal level 
of p38 phosphorylation, and BMP4 treatment decreased it. Previously, Rudarakanchana 
et al showed that transfection of mutant, but not wild-type, constructs into a mouse 
epithelial cell line (NMuMG cells) led to activation of p38 (MAPK) and increased serum-
induced proliferation25. As we discussed earlier, it is very possible that BMPRII knock 
down or mutation releases MAP3K8, mitogen-activated protein kinase kinase kinase 8, 
from binding of BMPRII into cytosol, which activates p38 pathway. We need to pursue 
further study on this subject whether this speculation would be right using 
immunoprecipitation and inhibitor studies for MAP3K8. Also it shows that there might 
be other receptors would be involved in activating MAPK pathway by BMP4 treatment.  
  
The major finding was that BMPRII knockdown inhibited monocyte adhesion and 
smad1/5/8 phosphorylation induced by BMP4, suggesting that BMPRII mediates the 
BMP4 effect (Fig. 3.1). These findings indicate that arterial inflammation could begin 
with BMP4 production in ECs exposed to disturbed flow conditions, priming the area for 
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development of the early stages of atherosclerosis 13.  In the continued presence of 
disturbed flow and other risk factors for atherosclerosis such as hypercholesterolemia, 
hypertension, diabetes and smoking, atherosclerotic lesions may progress and BMPRII 
expression level decreases, which can further exacerbate inflammation and 
atherosclerosis.   
 
 In summary, we show that BMPRII mediates BMP4-dependent inflammation.  
More interestingly, BMPRII knockdown in ECs induces inflammation in ROS, NFκB, 
and ICAM-1 dependent way. For the future studies, we will pursue the rescue 
experiments using bovine siRNA to knock down BMPRII in BAEC, and then infect with 
human BMPRII adenovirus to rescue BMPRII expression without any effect from the 
siRNA because of the species specificity.  
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Chapter 4 
 
Atherogenic Conditions Downregulate BMPRII expression.  
 
 
Introduction 
 
  
 Heterozygous mutations of BMPRII have been linked to familial and sporadic 
form of primary pulmonary hypertension (PPH) by both decreasing BMPRII expression 
as well as function1,2.  In addition, it has been reported that BMPRII expression is 
reduced in the lungs of the primary pulmonary hypertension patients even when they do 
not have any detectable mutations of the receptor 3. It seems that the condition of PPH 
may be correlated to regulation of BMPRII expression. In an animal model for 
pulmonary hypertension, Takahashi et al. showed that hypoxic condition in rats 
decreased BMPRII protein levels significantly4. There have been several evidences that 
showed decreased expression of BMPRII in both patients and animal models of PPH.  
  
 PPH is characterized by obliteration of pre-capillary pulmonary arteries, leading 
to sustained elevation of pulmonary arterial pressure and subsequent right ventricular 
hypertrophy. PPH is typically associated with abnormal proliferation of endothelial and 
smooth muscle cells within the small pulmonary arteries 5. Interestingly, PPH is also 
strongly associated with inflammation, as evidenced by accumulation of inflammatory 
cells infiltrating into the plexiform lesions in the lungs and increased inflammatory 
cytokines in the circulation of PPH patients 6.  Homozygotic deletion of BMPRII in mice 
causes an embryonic lethal phenotype 7, while heterozygotic BMPRII+/- mice show 
increased susceptibility to pulmonary hypertension in response to an inflammatory stress 
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8. These results provide a link between BMPRII mutation or haplo-insufficiency and PPH 
as well as an association between inflammation and PPH.  However, there is no published 
literature showing that BMPRII mutation or decreased BMPRII expression causes 
inflammation and atherosclerosis.  
  
 There have been studies on BMPRII expression in several research areas 
including cancer studies, HIV studies, and PPH. Down-regulation of BMPRII expression 
has also been seen in cancer patients. Several types of cancer cells such as renal 
carcinoma cells, bladder transitional carcinoma cells, and human prostate cancer cells 
showed decreased BMPRII expression 9-11. Also restoration of BMPRII using the 
demethylating agent 5-aza-2’-deoxycytidine led to a decreased rate in tumor growth10. In 
addition, there have been reports of down-regulation of BMPRII from human 
immunodeficiency virus (HIV) infection. Cadlwell et al. showed that HIV-Tat 
overexpression decreases BMPR2 promoter activity in U937 monocytes12.  Conversely, 
Hu et al. showed that whereas Simvastatin treatment decreased BMPRII reporter gene 
transcription,  it increased mRNA and protein expression in human lung microvascular 
endothelial cells13.  
 
 Based on these previous studies of pulmonary hypertension and cancer, we 
hypothesized that atherosclerotic conditions may be correlated to BMPRII expression in 
endothelial cells. We obtained human coronary artery sections with various stages of 
atherosclerosis to investigate BMPRII expression with progression of the disease. 
Interestingly, BMPRII expression decreased as atherosclerotic plaques advanced. This 
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result led us to form a new hypothesis that pro-atherogenic cytokines may be involved in 
regulating BMPRII expression in endothelial cells. Therefore, we challenged HUVECs 
using a potent cytokine, TNFα. On the other hand, anti-atherogenic drugs such as a lipid 
lowering drugs like statins, which have been shown to increase BMPRII expression, may 
have protective effects through BMPRII.   
 
 
Methods 
 
Cell culture: Human umbilical vein ECs (HUVEC) purchased from the Department of 
Dermatology, Emory University were cultured in M-199 supplemented with endothelial 
growth factor supplement, heparin, and 20% fetal bovine serum (FBS), and used between 
passages 3-6.   
 
Immunohistochemistry: Frozen sections of human coronary arteries (10 µm) were fixed 
in ice-cold acetone for 5 min, blocked for 1 hour with 10% donkey or goat serum, and 
incubated with primary antibodies overnight at 4°C, followed by rhodamine-conjugated 
secondary antibodies (anti-goat IgG, anti-mouse IgG or anti-rat IgG) for 2 hours at room 
temperature as described 14. Nuclei were counter-stained with Hoechst 33258 (Sigma). 
Primary antibodies used were specific for ALK2 (1:50, R&D systems), BMPRII (1:50, 
Santa Cruz) or PECAM-1 (1:50, BD). Twenty different human coronary artery sections, 
containing various stages of atherosclerosis from minimally diseased to advanced 
atheroma stages, from nine different patients, were examined.  Microscopic images were 
taken using a Zeiss epi-fluorescence microscope. The semi-quantification method was 
used based on the blind grading for atheroma intensity and BMPRII staining intensity in 
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endothelium using one to five scale (1: minimally diseased, low staining intensity, 5: 
advanced atheroma, high staining intensity).  
 
Western blot: Following experimental treatments, endothelial cell lysates were prepared 
and analyzed by Western blot analysis, as described by us 14,15. Briefly, cells were 
washed in ice-cold phosphate-buffered saline, and lysed in RIPA buffer, and protein 
concentration determined with a Bio-Rad DC assay. Aliquots of cell lysates were 
resolved on a SDS-PAGE gel and transferred to polyvinylidene difluoride membranes 
(Millipore). The membranes were probed with antibodies to BMPRII (1:1000, BD), 
phospho-eNOS (1:1000, Cell signaling), total-eNOS (1:1000, Cell signaling), or β-actin 
(1:1000, Santa Cruz), and appropriate secondary antibodies conjugated to alkaline 
phosphatase, which were detected by chemiluminescence method. 
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Results 
 
 
BMPRII levels are lower in endothelium of advanced atherosclerotic lesions than 
that in minimally diseased human coronary arteries. 
 
 To determine the pathophysiological significance of the in vitro finding that 
BMPRII knockdown induced inflammation, we examined whether BMPRII expression 
level changes in ECs in various stages of human atherosclerotic lesions. Serial frozen 
sections were obtained from human coronary arteries containing a spectrum of 
atherosclerotic lesion complexities, and examined by immunohistochemical staining with 
the BMPRII and PECAM-1 antibodies. In minimally diseased human coronary arteries, 
BMPRII staining was easily detected in luminal endothelium (arrows) and medial smooth 
muscle cells (Fig. 4.1 (B)-a).  BMPRII staining intensity in the luminal endothelium 
appeared to be less in Type II to III atheromatous lesions when compared to that of 
minimally diseased arteries (compare Fig 4.1 (A) a, d, g and Fig. 4.1. (B) a, d, g).  
Furthermore, BMPRII staining in the luminal endothelium was nearly undetectable in 
advanced atheromatous lesions, (Fig. 4.1 (B)-g).  Quantification of the BMPRII staining 
intensities in the luminal endothelium in various sections (n=17) showed a negative 
correlation (r2=0.68) with respect to the atheroma lesion stages (Fig. 4.1 (C) Graph).  
These results suggest that BMPRII expression decreases as atherosclerotic lesion 
progresses, reaching an undetectable level in the advanced lesion stage. 
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Figure 4.1. BMPRII levels are lower in endothelium in advanced atherosclerotic 
lesions than that in minimally diseased human coronary arteries. (A) Human 
coronary arteries with various stages of atherosclerotic plaques were stained with 
BMPRII (1:50, scbt), ALK2 (1:50, R&D systems), and PECAM-1 (1:50, BD Pharmingen) 
antibodies. These are composite figures from multiple 10x pictures taken by Zeiss epi-
fluorescence microscope. Close-up images from the boxed areas are shown in Fig. 4.1 (B) 
 
 
 
A 
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Figure 4.1. (Continued) BMPRII levels are lower in endothelium in advanced 
atherosclerotic lesions than that in minimally diseased human coronary arteries. (B) 
Close-up images from the boxed areas are shown (10x), Arrows indicate endothelium and 
L stands for the vessel lumen. 
 
B 
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Figure 4.1. (Continued) BMPRII levels are lower in endothelium in advanced 
atherosclerotic lesions than that in minimally diseased human coronary arteries. (C) 
In total, 21 sections were stained, but 17 sections were blindly graded. Atheroma 
intensity: 1-minimally diseased to 5-advanced plaque, BMPRII expression: 1- low to 5- 
high. 
 
 
A potent cytokine, TNFα, decreases BMPRII expression in HUVECs. 
 
Based on the results from BMPRII staining of various stages of human coronary 
arteries, we speculated that BMPRII expression may be regulated by atherogenic 
conditions. Therefore, we decided to test the hypothesis that two potent cytokines, Tumor 
Necrosis Factor α (TNFα) and Lipopolysaccharide (LPS), which are known to increase 
inflammation, may be responsible for decreasing BMPRII expression. 
 As shown in Figure 4.2 (A), TNFα treatment decreased BMPRII expression in 
HUVEC. After 24 hour of treatment, BMPRII expression was decreased about 50% 
compared to control. LPS treatment, however, had a tendency to decrease BMPRII 
expression only slightly; while there was a trend, it was not statistically significant (Fig 
4.2 (B)). These results support our hypothesis that atherosclerotic cytokines decrease 
BMPRII expression in endothelial cells.  
C 
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Figure 4.2. A potent cytokine, TNFα, decreases BMPRII expression in HUVECs. (A) 
Confluent HUVECs were treated with TNFα (20 ng/ml and 60 ng/ml) for 1 hr, 4 hr, and 
24 hrs. Cells were harvested in RIPA buffer and protein lysates were analyzed by 
Western blot using BMPRII (1:1000, BD pharmigen) and actin (1:1000, scbt) antibodies. 
Densitometry and statistical analysis were performed (n=6, *, p<0.05). (B) Confluent 
HUVECs were treated with LPS (100ng/ml and 1mg/ml) for 24 hrs. Cell lysates were 
processed and analyzed as described in A). (n=4, *, p<0.05) 
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Statins increase BMPRII expression in HUVECs. 
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Figure 4.3. Statins increase BMPRII expression in HUVECs. (A) Confluent HUVECs 
were treated with 10µM mevastatin for 24 hrs. Total RNA was isolated and real-time 
PCR was performed (*, p<0.05, n=4). (B) Cells were treated the same way as in (A) and 
then immunoblot analysis was performed as in Fig 5.2 (*, p<0.05, n=4). C) Confluent 
HUVECs were treated with several concentrations of simvastatin (Calbiochem), and 
rosuvastatin (gift from Dr. Searles). (*, p<0.05, n=6). 
 
  
Hu et al. previously showed that simvastatin increases BMPRII expression in 
human lung microvascular endothelial cells13. Figure 4.3 (A) shows that mevastatin 
(10µM) treatment for 24 hours in HUVECs increased BMPRII mRNA approximated 
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40% as measured by quantitative PCR. BMPRII protein levels were also increased with 
mevastatin treatment by about 250% (Fig.4.3 (B)). We then tested two other statins, 
simvastatin and rosuvastatin. Simvastatin is categorized as hydrophobic; whereas, 
rosuvastatin is hydrophilic. As shown in Figure 4.3 (C), simvastatin increased BMPRII 
expression by about 350% at as low a concentration as 1µM. Also, rosuvastatin increased 
BMPRII expression to the same level as simvastatin at a concentration of 10µM. This 
suggests that simvastatin is 10-fold more potent in increasing BMPRII expression. 
 
 
Mevalonate blocks simvastatin-induced BMPRII overexpression. 
  
Statins are inhibitors of HMG-CoA reductase, which is the rate-limiting enzyme 
in the cholesterol synthesis pathway that converts HMG-CoA to mevalonate (figure 4.4 
(A)). To show that statins’ upregulation of BMPRII expression is due to inhibition of the 
HMG-CoA reductase pathway, we treated HUVECs with simvastatin along with 
mevalonate. As shown in Figure 4.4 (B), simvastatin treatment increased BMPRII 
expression by about 400%, and concurrent mevalonate treatment with simvastatin 
completely blocked simvastatin-induced BMPRII up regulation. This result suggests that 
upregulation of BMPRII by statins is mediated by the cholesterol synthesis pathway.  
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Figure 4.4. Mevalonate blocks simvastatin-induced BMPRII overexpression. (A) A 
diagram of cholesterol synthesis pathway. (B) Confluent HUVECs were treated with 
10µM simvastatin with or without mevalonate for 24 hrs. Cell lyasates were collected 
and then immunoblot analysis was performed (*, p<0.05, n=4). 
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BMPRII knockdown attenuates LS-induced eNOS phosphorylation.  
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Figure 4.5. BMPRII knockdown attenuates LS-induced eNOS phosphorylation. 
HUVECs were transfected with non-silencing siRNA or BMPRII siRNA (50nM) for two 
days, and then exposed to uni-directional laminar shear for 24hrs. Cell lyasates were 
collected and then immunoblot analysis was performed (*, p<0.05, n=3). 
 
 
 
 Previously, it has been shown that statins increase eNOS expression and 
activity16,17. From our statin studies, we showed that statins increase BMPRII expression. 
Therefore, we speculated that BMPRII expression may affect eNOS expression. When 
we knocked down BMPRII, there was no effect on eNOS expression under basal 
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conditions. However, BMPRII siRNA-transfected cells exposed to LS showed less 
phosphorylated eNOS expression compared to Non-silencing controls (Fig 4.5). This data 
suggests that in PPH patients, vascular dysfunction might be due to decreased eNOS 
activity induced by decreased expression of BMPRII. 
 
 
Discussion 
 
The major findings reported in this study are that a) BMPRII expression is 
progressively lost as athermanous lesions advance in human coronary arteries, b) the 
cytokines TNFα decrease BMPRII expression in HUVECs, c) statins increase BMPRII 
expression through a HMG-coA reductase dependent pathway, and d) knockdown of 
BMPRII decreases eNOS phosphorylation by LS. Collectively, these findings show that 
BMPRII protein level is regulated in endothelium and may be negatively correlated with 
atherosclerotic lesion development.  
 
Downregulation of BMPRII has been shown in familial and sporadic primary 
pulmonary hypertension as well as some types of cancers such as prostate and bladder 
cancers. However, it has not been shown that atherosclerotic plaques also lose BMPRII 
expression. It is highly possible that a proliferative cell state might be responsible for 
down regulation of BMPRII expression because proliferation is one of the phenotypes 
that is common among three areas of research-pulmonary hypertension, cancer and 
atherosclerosis. However, here, we are suggesting that inflammatory cytokines also 
decrease BMPRII expression in endothelial cells.  
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 We have shown here that pro-inflammatory cytokines, TNFα, decreased BMPRII 
expression in HUVECs (Fig. 5.2).  Several reports of BMPRII downregulation have been 
reviewed, especially in pulmonary hypertension and cancer research2,3,4, 9-11.  In this study, 
we also showed that atherosclerotic conditions downregulate BMPRII expression using 
human coronary arteries with various atheroma developments (Fig. 4.1).  
 
Atherosclerosis is a long term disease process which involves risk factors such as 
hypertension, age, smoking, and hyperlipidemia. Also, other risk factors that could 
contribute to a further understanding of vascular pathology include markers of 
inflammation and growth factors. In this study, we showed the effects of only TNFα 
effects on BMPRII expression; however, for future studies, we may need to determine the 
effects of various cytokines such as interleukin family members (IL-2, IL4, IL-6, IL-8, 
IL-10, IL-1α, IL-1β), vascular endothelial growth factor (VEGF), epidermal growth 
factor (EGF), interferon-γ (IFNγ), and monocyte chemotactic protein-1 (MCP-1). We 
also may need to ask how important other risk factors, such as hyperlipidimia and 
hypertension, are in regulating BMPRII expression as well as to what extent BMPRII 
contributes in a protective role during atherogenesis. 
  
Interestingly, in our lab, we have shown that BMP4 levels increase with the 
progression of atherosclerosis in human coronary arteries18. In those studies, ECs in the 
lesser curvature exposed to disturbed flow, but not those in the greater curvature and 
straight arterial regions exposed to undisturbed flow, showed coexpression of BMP4 and 
BMP antagonists. Similarly, in human coronary arteries, expression of BMP4 and BMP 
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antagonists in ECs positively correlated with the severity of atherosclerosis. San Martin 
et al. showed that in db/db mice (Type 2 diabetes model) BMP4 levels increased with the 
progression of diabetes, and after 8 week of treatment with the superoxide scavenger 
Tempol, 12-week old db/db mice had lower BMP4 protein expression when compared to 
non-treated mice19.  
 
 On the other hand, Grainger et al. showed that TGF-ß, which is included in the 
same family member as BMP4, decreases with the development of atherosclerosis. They 
postulated that TGF-ß played an important role in maintaining normal vessel wall 
structure and that loss of this protective effect contributed to the development of 
atherosclerosis20. Kulkarni et al. generated TGF-β knock-out mice and showed a 
widespread inflammatory reaction in multiple organs causing cardiopulmonary death at 
3-4 weeks of age due to profound pathology in heart and lungs21. However, Bobik et al. 
suggested contradictory findings, that TGF-ß is most active in fatty atherosclerotic lesions 
of the human aorta, showing properties of proatherogenic cytokine, promoting the 
retention of lipoprotein22.  
 
In this study, we have not shown that BMPRII has a protective effect on 
atherogenesis. However, we did show that statins increase expression of BMPRII in 
HUVECs (Fig. 4.3). For future studies, we will need to focus on the protective effect of 
BMPRII by using other drugs which may be regulate over expression of BMPRII as well 
as mouse models where BMPRII is overexpression in both endothelial cells and smooth 
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muscle cells. However, to our knowledge, there are no BMPRII overexpressing mice 
models.  
 
The mechanisms of statins’ effects on eNOS expression and activity have been 
studied. Because statins inhibit an early step in the cholesterol biosynthetic pathway, they 
also inhibit the synthesis of isoprenoids such as farnesylpyrophosphate and 
geranylgeranylpyrophosphate, which are important posttranslational lipid attachments for 
intracellular signaling molecules such as the Rho GTPases. Indeed, a decrease in Rho 
GTPase responses as a consequence of statin treatment increases the production and 
bioavailability of endothelium-derived NO. The mechanism involves, in part, Rho/Rho-
kinase (ROCK)-mediated changes in the actin cytoskeleton, which leads to decreases in 
eNOS mRNA stability. The regulation of eNOS by Rho GTPases, therefore, may be an 
important mechanism underlying the cardiovascular protective effect of statins23. Laufs et 
al. showed that Rho negatively regulates eNOS expression and statins up-regulate eNOS 
expression by blocking Rho geranylgeranylation, which is necessary for its membrane-
associated activity24.  
  
As such, the Rho/ROCK pathway has gained important prominence as a 
promising therapeutic target in cardiovascular diseases. Here, we showed that statins 
increase BMPRII expression and also BMPRII knockdown decreased, LS-induced eNOS 
phosphorylation compared to non-silencing siRNA controls. This indicates that BMPRII 
might have a protective effect through eNOS. Statin treatment may increase eNOS 
activity through a BMPRII/Rho/ROCK dependent pathway. However, our preliminary 
 87
data shows that statins alone increase adhesion molecules, including ICAM-1 and 
VCAM-1. This area of study seems to be controversial because several groups have 
shown that statin treatment increases adhesion molecules and inflammatory responses25-27, 
but many groups have also shown that statins actually protect from inflammation by 
cytokine treatment with TNFa or high glucose28,29. We will need more thorough studies 
to determine the mechanism of statin’s effects on BMPRII. 
 
In summary, we show that BMPRII levels decrease in atherosclerotic ECs and 
that pro-atherogenic cytokine, such as TNFα decrease BMPRII expression. On the other 
hand, statin treatment increased BMPRII expression, and BMPRII knockdown decreased 
eNOS phosphorylation by LS indicating that statin might have effects on eNOS through 
BMPRII. Therefore, BMPRII expression in EC’s could be used as a novel biomarker of 
atherosclerosis and also BMPRII overexpression may have a protective role during 
atherogenesis, which is a subject that needs more thorough investigation.  
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Chapter 5 
 
In vivo mouse model for BMPRII regulation and atherosclerosis 
 
 
Introduction 
 
  
Atherosclerotic cardiovascular disease is the main cause of death in the Western 
world. Atherosclerosis is a chronic inflammatory disease, which develops slowly, 
resulting in cumulative atheromatous plaques. These plaque formations usually begin in 
childhood, well before the age of 10, and progress over time. Autopsies of healthy young 
men who died during the Korean and Vietnam Wars already showed coronary disease1. 
Endothelial dysfunction causes leukocytes and monocytes to adhere and infiltrate into the 
intima, under the endothelium, to develop atherosclerotic lesions, filled with excess lipids, 
smooth muscle cells, and collagen deposition. As the plaques grow and narrow the lumen, 
blood flow in the arteries is hindered. If they rupture and travel to smaller arteries and 
block the blood flow, this can cause heart attack or stroke. 
 
 There have been studies investigating atherosclerotic cardiovascular disease in 
many animal models, including nonhuman primates, swine, dogs, rabbits, rats and mice. 
The ideal animal model of cardiovascular disease will mimic the human disease process 
metabolically and pathophysiologically, and will develop end-stage disease comparable 
to that in the human. Among these, pigs and monkeys are the best models resembling the  
human atherosclerotic process; however, the high cost and difficulties with handling the 
animals are hinderances for large amounts of research2. Therefore, the possibility of a 
murine (mouse) atherosclerosis model was suggested. Generally, mice are highly 
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resistant to atherosclerosis because they normally have a high percentage of high density 
lipoprotein (HDL), carrying most of the plasma cholesterol on HDL; in comparison, 
humans carry about 75% of their plasma cholesterol on low density lipoprotein (LDL). 
Early atherosclerotic mouse models were limited to C57BL/6 mice with special diets of 
30% fat, 5% cholesterol, and 2% cholic acid in Wissler’s laboratory. Later Paigen et al. 
modified this to the “Paigen diet”, consisting of 15% fat, 1.25% cholesterol, and 0.5% 
cholic acid. Paigen et al. screened ten inbred strains of mice for their ability to form fatty 
streaks and C57BL/6 mice reached a fatty streak stage at the aortic root within 14 weeks 
to 9 months on this diet3. However, the lesions from these mice consist of macrophage 
foam cells without any proliferation of smooth muscle cells into the intima, also, and 
atherogenic diet is necessary to induce atherosclerosis. There have been several 
genetically engineered atherosclerotic mouse models developed, including ApoE knock 
out, LDL receptor knock out, and ApoE *3Leiden mice. In 1992, Piedrahita et al. and 
Plump et al. developed ApoE knock out mouse4,5. ApoE is a structural component of all 
lipoprotein particles which coats them, functioning as a ligand for receptor-mediated 
uptake of chylomicron and VLDL remnants, as well as apoE-rich HDL. Jawien et al. 
showed that in ApoE knock out mice, the lipid profile was shifted from high HDL and 
low LDL contents to mostly vLDL6. As a result, total plasma cholesterol level in ApoE 
knock out mice increase 5-fold compared to normal mice. Triglycerides increase by about 
2-fold, as shown in table 5.1.  
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Table 5.1. Lipid profile from ApoE knock mice with chow diet. Taken from reference 
6.  
 
  
 Later on, Dansky et al. showed that according to genetic background, even among 
ApoE knock out mice, mice respond differently to atherosclerosis development7. They 
compared FVB/NJ and C57BL/6J backgrounds of ApoE knock out mice. Although 
FVB/NJ background mice had higher cholesterol levels than C57BL/6J background mice, 
the atherosclerotic lesion areas were less in FVB/NJ mice compared to C57BL/6J at 16 
weeks of age. The advantage of ApoE knock out mice is that they develop atherosclerosis 
without a high-cholesterol diet. As shown in Figure 5.1, at 3 months of age, ApoE knock 
out mice start to develop macrophage accumulation in the aortic sinus (Fig 5.1.b) 
compared to the ApoE +/+ control litter mates (Fig 5.2.c) which did not develop any 
signs of atherosclerosis at 6 months.  At 10 months of age, ApoE -/- mice develop 
plaques in the ascending aorta and carotid arteries as well in the aortic sinus (Fig 5.2 d, e, 
and f). 
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a) Normal, aortic sinus,
6 month
c) Apo E KO, aortic sinus, 
5 month
d) Apo E KO, aortic sinus,
10 month
b) Apo E KO, aortic sinus, 
3 month
e) Apo E KO, ascending aorta,
10 month
f) Apo E KO, carotid artery,
10 month  
Figure 5.1. Lipid staining of aortic sinus, ascending aorta, and carotid artery 
sections from various ages of ApoE knock out mice on chow diet. This figure is 
reconstructed from Reddick et al.’ paper8.  
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Figure 5.2. Sites of predilection for lesion development are indicated in black: 1) 
aortic root, at the base of the valves; 2) lesser curvature of the aortic arch; 3) principal 
branches of the thoracic aorta; 4) carotid artery; 5) principal branches of the abdominal 
aorta; 6) aortic bifurcation; 7) iliac artery; and 8) pulmonary arteries. This is taken from 
Nakashima et.al9.  
 
 Figure 5.2 shows areas of atherosclerotic lesion development throughout the 
vasculature in mice. Similar to human atherosclerotic plaque development, mice develop 
lesions preferentially in disturbed flow areas such as the aortic sinus, curvature, and 
bifurcation.  If ApoE knock out mice are fed a high-fat atherogenic diet, plaque 
development can be accelerated by about two to five weeks, as shown in Figure 5.3. 
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Figure 5.3. Diagram showing how lesion formation in chow-fed mice is delayed in 
comparison with mice fed a Western-type diet. The diagram shows the time periods 
over which indicated lesion types were observed. This diagram is taken from Nakashima 
et.al9.  
 
 The LDL receptor knock out mouse is a model of human familial 
hypercholesterolemia developed by Ishibashi et al. in 1993. LDL receptor knock out mice 
do not get atherosclerosis with chow diet; however, extensive hypercholesterolemia and 
lesion formation can be induced by high-fat diet whereas ApoE knock out mice are 
characterized by spontaneous hyperlipidemia and atherosclerosis. 
 Apo E *3Leiden mice carry mutant forms of human apoE. ApoE *3Leiden is a 
tandem duplication of codons 120 through 126 in the apoE gene, and the presence of a 
single allele for this mutation results in the expression of familial dyslipoproteinemia. 
Dysfunctional apoE Leiden has high affinity over wild-type apoE for triglyceride-rich 
lipoproteins. ApoE*3 Leiden mice are less susceptible to lesion development than ApoE 
KO mice, which develop lesions even on a normal chow diet. ApoE*3 Leiden mice have 
the ability to synthesize functional endogenous apoE.  
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 Even though these mice follow the human atherosclerotic disease process to some 
extent, mouse models do not develop the same end-stage ischemic heart lesions, 
including occlusive coronary artery disease, myocardial infarction, cardiac dysfunction, 
and premature death. Atherosclerotic lesions can be categorized in several types; Type I 
are initial lesions with isolated macrophage foam cells, Type II have fatty streaks with 
mainly intracellular lipid accumulation, Type III are intermediate lesions with type II 
changes and small extracellular lipid pools, Type IV are atheromas with Type II changes 
and a core of extracellular lipid, Type Va are fibroatheromata with lipid cores and fibrotic 
layers, Type Vb are mainly calcific Vc: fibrotic fibroatheromata, and Type VI have 
plaque rupture, thrombus formation and hemorrhage10. Also, it has been controversial as 
to whether mice develop plaque rupture of Type VI lesions. Schwartz et al. recently 
published a very extensive review on plaque rupture in mice11.  
 
 To overcome these disadvantages in a diet-induced genetically engineered mouse 
model and to develop a model which mimics human atherosclerotic plaques, there have 
been several papers published using mechanical intervention in the arteries. Vascular 
remodeling, neointima formation, and atherosclerosis have been studied in mice whose 
arteries are injured from angioplasty, carotid artery ligation, or cuff placement. 
Leidenfrost et al. showed that temporary ligation yielded a significant luminal narrowing 
and the lesion was more advanced, with inclusion of foam cells, cholesterol clefts, 
necrotic cores, and fibrous caps, than the de novo plaques produced by diet alone12. In 
addition, this approach generated a significant plaque in 3 weeks compared to 6 to 12 
months needed with high-fat diet alone. When the high fat diet was stopped after 
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angioplasty, the vessels generated a densely cellular, hyperplastic lesion analogous to the 
neointimal thickening seen in human restenosis, but with high fat diet, intimal lesions 
resemble fatty streaks and not hypercellulear, fibrotic intimal lesions seen with restenosis 
in humans. Primary atherosclerotic intima shows less smooth muscle cells and more 
macrophage-derived foam cells. Also, Chen at al. showed that shear stress is responsible 
for composition of plaques13. They used a cast to change shear stress levels in the mouse 
carotid artery, and showed that oscillatory shear stress makes more lipids and 
macrophage-type plaques, while low shear stress makes more smooth muscle cells and 
collagen-type plaques.  
 
 These mechanically induced injury models also give us very useful tools to study 
the effects of atherogenic factors on disease progression and also to test candidate 
hypolipidemic and antiatherosclerotic drugs. Because of the intrinsic differences in 
anatomy and physiology between the human and mouse, it seems necessary to use several 
model systems to study the atherosclerotic disease process. 
 The importance of BMPRII in pulmonary hypertension has recently been 
supported by transgenic studies. BMPRII knock out mice are embryonic lethal; therefore, 
Beppu et al. developed a heterozygote BMPRII mice model 14,15. Song et al. and Long et 
al. showed that these mice have increased susceptibility to pulmonary hypertension in 
response to either serotonin or inflammation induced by lipoxygenase adenovirus 
delivery, respectively 16,17. Also, West el al. developed a tetracycline-responsive, smooth 
muscle-specific dominant-negative BMPRII mouse18. When these mice were fed 
doxycycline, they developed pulmonary hypertension. Later, from the same group, Tada 
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et al, performed a gene array analysis of whole lung mRNA from mice with the transgene 
activated for 1 or 8 weeks compared to non-activated mice 19. Their major findings were 
that in these lungs, they lose markers of smooth muscle differentiation but increase 
inflammatory gene expression. In addition, Reynolds et al, performed BMPRII 
adenoviral gene therapy in hypoxia- induced pulmonary hypertension rat models, and 
showed that up-regulation of BMPRII could reduce pulmonary hypertension but could 
not completely reverse it to a normal state20.  
 
 In this study, we have decided to expand our findings from in vitro cell culture 
and human atherosclerosis studies to in vivo mouse model studies. For the first part of the 
study, we hypothesized that hyperlipidimic conditions in Apo E knock out mice or 
vascular injury induced by carotid artery ligation might be responsible for decreased 
expression of BMPRII in endothelial cells. For the second part of the study, we obtained 
BMPRII heterzygote mice from Dr. Beppu at Harvard University to test whether 
decreased expression of BMPRII is responsible for inflammation and acceleration of 
atherosclerosis.  
 
Method 
 
Animal studies for diet induced atherosclerosis model: Male Apolipoprotein E–null 
(ApoE–/–) mice from Jackson Laboratory (Bar Harbor, Me) were purchased at the age of 6 
weeks. All experimental protocols were approved by the Institutional Animal Care and 
Use Committee at Emory University. Mice were fed Paigen’s atherogenic diet from 
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Research Diets (New Brunswick, NJ) for 2 weeks, 4 weeks, 8 weeks and 6 months.  The 
animals were humanely killed by CO2 inhalation at the end of treatment.  
 
Partial carotid ligation model: 6 weeks old female ApoE knock out mice were 
purchased from Jackson Laboratory (Bar Harbor, Me). On the day of surgery, anesthesia 
was induced by using a Ketamine/Xylazine mixture injected intraperitoneally. After hair 
removal from the neck of each mouse, one-inch mid-line incision was made from the 
level of the larynx down to the clavicle. A blunt dissection was done just left of the 
trachea, with resultant exposure of the left common carotid and its caudal divisions. The 
left internal carotid, external carotid and occipital arteries were ligated with 6-0 silk 
suture. For matching sham surgery controls, ligation was not done, but blunt dissection 
was performed as noted above. The skin was closed with 6-0 silk suture using simple, 
interrupted stitches. A Western diet was started on the day of surgery to accelerate 
atherosclerosis. Mouse carotid arteries in OCT blocks were then collected at different 
time points for analysis. 
 
Immunohistochemistry: Frozen sections of mouse aortas and carotid arteries (10 µm) 
were fixed in ice-cold acetone for 5 min, blocked for 1 hour with 10% donkey or goat 
serum, and incubated with primary antibodies overnight at 4°C, followed by rhodamine-
conjugated secondary antibodies (anti-goat IgG or anti-rat IgG) for 2 hours at room 
temperature as described 21. Nuclei were counter-stained with Hoechst 33258 (Sigma). 
Primary antibodies used were specific for BMPRII (1:50, Santa Cruz) or PECAM-1 (1:50, 
BD).  Microscopic images were taken using a Zeiss epi-fluorescence microscope. The 
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semi-quantification method was used to grade BMPRII staining intensity in endothelium 
using one to five scales (1: low staining intensity, 5: high staining intensity). 
 
 
Results 
 
High-fat diet increases total cholesterol, LDL, and VLDL, but decreases HDL and 
triglycerides in ApoE knock out mice.    
  
 From the high-fat diet induced atherosclerosis mouse studies using ApoE knock 
out mice, we collected blood samples at the time of sacrifice. The average serum 
cholesterol at baseline with chow diet was between 600 and 1000 mg/dL, with no 
significant differences between groups. As expected, high-fat diet had a dramatic increase 
in total serum cholesterol between 1400 and 2600 mg/ml. As shown in Figure 6.4, total 
cholesterol levels went down over time, peaking at 2 weeks in high-fat diet mice. Since 
we analyzed plasma samples on a different date, it is necessary to confirm this data. 
Interestingly, LDL and vLDL levels also decreased with time with high-fat diet, while 
HDL levels increased. Unexpectedly, triglyceride levels in chow-diet mice were higher 
than those in the high-fat diet group. We do not know whether this is a specific effect of 
the diet we used. However, this data clearly shows that high-fat diet induced 
hyperlipidemia in Apo E knock out mice.  
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Figure 5.4. Total cholesterol, LDL, and VLDL levels increased in high fat diet ApoE 
knock out mice compared to chow diet, while HDL decreased.  Serum lipid profiles, 
including total serum cholesterol, HDL, LDL, vLDL, and triglycerides, were measured at 
2 weeks, 4 weeks and 8 weeks for chow-diet or high-fat diet ApoE knock out mice. Three 
to five representative samples were analyzed from each group (Chow: Chow diet, HC: 
High-fat diet) 
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BMPRII expression decreases in aortas with aging of ApoE knock out mice. 
 
Figure 5.5. BMPRII expression decreases in aortas with age in ApoE knock out mice. 
Aortas from ApoE knock out mice with chow or high fat diet at 2 weeks, 4 weeks, or 8 
weeks were stained with BMPRII (1:50, Santa Cruz) antibody. These are 40x pictures 
taken with a Zeiss epi-fluorescence microscope. Arrows indicate endothelial cells, and L 
stands for the vessel lumen. Aortas are from ApoE knock out mice with (a) 2 weeks of 
chow diet, (b) 2 weeks of high fat diet, (c) 4 weeks of chow diet, (d) 4 weeks of high-fat 
diet, (e) 8 weeks of chow diet, and (f) 8 weeks of high-fat diet.  
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Figure 5.5. (Continued) BMPRII expression decreases in aortas with age in ApoE 
knock out mice. Aortas from ApoE knock out mice with chow or high fat diet at 2 weeks, 
4 weeks, or 8 weeks were stained with BMPRII (1:50, Santa Cruz) antibody. These are 
40x pictures taken with a Zeiss epi-fluorescence microscope. Arrows indicate endothelial 
cells, and L stands for the vessel lumen. (g) A total of 24 sections were stained and 
blindly graded. BMPRII expression: 1- low to 5- high. (h) Aortas from 1 year old ApoE 
knock out mice were stained with BMPRII. (i) Close up pictures from the box area in 
Figure 5.5 (h) taken at 40x magnification. Arrows indicate endothelium and L stands for 
vessel lumen.  
 
 
 Next, we examined BMPRII expression from the aortas of ApoE knock out mice 
on chow or high-fat diet. As shown in Figure 5.5, endothelial cells after 2 weeks of either 
chow or high fat diet expressed the highest levels of BMPRII, as indicated by pink 
staining (arrows in Figure 5.5 (a) and (b)). BMPRII expression decreased after 4 weeks or 
8 weeks on chow or high fat diet, as shown in Figure 5.5 (c) through (f). A total of 
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twenty-four aorta sections for six conditions were graded blindly by three people.  
Quantification of BMPRII staining intensities in the luminal endothelium in various 
sections showed a decrease with respect to the age (Fig.5.5 (g) Graph). However, there 
was no difference between chow diet and high-fat diet. These results suggest that 
BMPRII expression decreases with age in ApoE knock out mice. As shown in Figure 5.5 
(h) and (i), 1 year old ApoE knock out mice had an undetectable levels of BMPRII with 
advanced lesions. These data support our hypothesis that with atherosclerotic disease 
progression, BMPRII expression in endothelial cells is decreased.  
 
 
 
 
Preliminary BMPRII staining from partial carotid artery ligation model 
  
 Carotid arteries from the partial ligating model were stained with BMPRII 
antibody to investigate protein expression levels. In this model, the left carotid artery was 
ligated, and the right artery was undamaged at the time of surgery. As shown in Figure 
6.6, after 5 days of ligation, the right carotid artery was enlarged compared to the sham 
surgery. On the eighth day after surgery, the left carotid artery started to develop vascular 
remodeling and atherosclerosis. In addition, BMPRII expression was decreased in the left 
carotid artery compared to right side on the eighth day. These data are from one animal 
for each condition; therefore, we will need to confirm the results with more animals.  
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Figure 5.6 Preliminary BMPRII stain from partial carotid artery ligation model. 
Carotid arteries 5 days and 8s day after sham and ligating surgery of ApoE knock out 
mice were stained with BMPRII (1:25, Santa Cruz) antibody. These are figures from 20x 
pictures taken with a Zeiss epi-fluorescence microscope.  
 
 
Discussion 
  
From these in vivo atherosclerotic mouse studies, we showed that a) ApoE knock 
out mice on high- fat diet develop exacerbated hyperlipidimic conditions after 2 weeks of 
diet compared to chow diet (Fig 5.1), b) foam cell development with age and high-fat diet 
appear to be responsible for decreased expression of BMPRII in endothelial cells in 
ApoE knock out mice (Fig 5.2), and c) a preliminary study from a  carotid ligation model 
showed that with medial thickening and atherosclerosis development, BMPRII 
expression decreased in endothelial cells as well as in smooth muscle cells (Fig. 5.3). 
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From our previous studies using human coronary arteries in chapter 4, we showed 
that BMPRII expression is lost in both smooth muscle cells and endothelial cells with the 
advanced atheroma development. However, our in vivo ApoE knock out mouse studies 
showed that decreased BMPRII expression is more evident and faster in endothelial cells 
than smooth muscle cells. Although this is a very preliminary study, our carotid ligation 
model seems to give us similar results to human coronary arteries. We think that any 
discrepancies may come from the differences inherent in the animal model. 
 
These animal model approaches are trials to simulate the human atherosclerotic 
process. Though these studies give very important insights into how atherosclerosis 
develops, validation of certain findings in several animal models and human beings is 
necessary. Therefore, we have decided to also employ a partial carotid ligation model for 
atherosclerotic development in mice.  
There are several in vivo mouse models that accelerate the atherosclerotic process 
through surgical intervention of blood flow.   
Ligation of the carotid artery is used in vivo to block blood flow and, afterwards, 
to examine the response of vascular remodeling.  In mice, sufficient blood flow still 
reaches the brain through other vessels so that the ligation is not fatal. This model of flow 
cessation causes the induction of proteases, intimal hyperplasia, and macrophage 
infiltration, all with an intact endothelium 22-25. In addition, low flow models in vivo have 
been accomplished by partial ligation of the carotid arteries 26 or by ligation of internal 
carotid artery and three of the other branches of the external carotid artery 27.  Partial 
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outflow occlusion models also lead to lower flow through the artery of interest 28.  
Among these, we have started a partial carotid ligation model, and we have some 
preliminary data showing changes in BMPRII expression. 
 
Moreover, for on going and future studies, we have begun to feed BMPR-II 
heterozygote mice and C57BL/6 control mice with high-fat diet for 8 weeks. We are 
planning to look at lipid profiles, en face Oil-Redo staining for overall evaluation of 
atherosclerosis, and macrophage infiltration and atherosclerosis in the aortic sinus. Also, 
we are planning to pursue partial carotid ligation surgeries to compare BMPR-II 
heterozygote mice and C57BL/6 control mice in terms of atherosclerotic progression. In 
addition, we are breeding BMPRII heterozygote mice and ApoE knock out mice to 
accelerate atherosclerosis in our model. With these mice, we will look at atherosclerosis 
as well as pulmonary hypertension in collaboration with Dr. Beppu at Harvard School of 
Medicine. 
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Chapter 6 
 
Discussion and Future Studies 
 
 
The novel findings of this study are that, a) OS increases nox1 and nox2 mRNA 
expression while decreasing nox4, b) BMP4 increases only nox1 mRNA level, c) 
knocking down nox1 blocks OS-induced monocyte adhesion, d) knocking down BMP4 
inhibits OS-induced ROS production and prevents monocyte adhesion, e) aortic ECs 
express ALK2, ALK6 and BMPRII, and f) knockdown of BMPRII blocks BMP4-
dependent smad1/5/8 phosphorylation and monocyte adhesion.  Unexpectedly, we found 
that g) BMPRII knockdown in MAEC and HUVEC unleashes an inflammatory response 
in the absence of BMP4 and that h) BMPRII expression is progressively lost as 
atheromatous lesions advanced in human coronary arteries.   In addition, i) cytokines, 
TNFα and LPS decrease BMPRII expression in HUVECs, j) statins increase BMPRII 
expression through an HMG-CoA reductase-dependent pathway, and k) knockdown of 
BMPRII decreases eNOS phosphorylation by LS.  
 
Collectively, these novel findings strongly suggest that BMP4, produced in 
endothelial cells in response to OS, acts as a pro-inflammatory cytokine by stimulating 
ROS production in a nox1-dependent manner, eventually leading to a monocyte adhesion 
response.  Also, we show that BMPRII mediates BMP4-dependent inflammation.  More 
interestingly, BMPRII knockdown in ECs induces inflammation. We show for the first 
time that a decrease in BMPRII protein level in aortic endothelium is linked to 
inflammation and atherosclerosis.  Therefore, BMPRII expression in EC’s could be used 
as a novel biomarker of atherosclerosis. Furthermore, BMPRII overexpression might 
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have a protective role during atherogenesis, a speculation that warrants more thorough 
investigation.  
 Atherosclerosis is now well known to be an inflammatory disease preferentially 
occurring in lesion-prone areas associated with unstable shear stress in branched or 
curved arteries.  In addition, increased levels of ROS have been strongly implicated in 
atherosclerotic plaque development1.  In our previous study2, we found that monocyte 
adhesion by endothelial cells in response to OS was observed only after a chronic 
exposure (18 hrs or longer), but not by a shorter exposure (4 hrs), suggesting a 
requirement for de novo synthesis of proteins such as BMP4.  Consistent with this idea, 
we have recently provided evidence that BMP4 induction, requiring several hours of OS 
exposure, is responsible for triggering the monocyte adhesion response in endothelial 
cells3.  Furthermore, our current data, showing a significant increase in ROS production 
following 20 hrs of BMP4 treatment, may be due to an increase in nox1 mRNA level. 
Taken together, these results demonstrate a critical role for BMP4 in mediating OS-
dependent ROS production and inflammatory responses.   
 
 Recently, heterozygous BMPRII mutations have been linked to familial and 
sporadic primary pulmonary hypertension (PPH) 4,5.  In addition, it has been reported that 
BMPRII expression is reduced in the lungs of  primary pulmonary hypertension patients 
even when they do not have any detectable mutations of the receptor 6. PPH is 
characterized by obliteration of pre-capillary pulmonary arteries, leading to sustained 
elevation of pulmonary arterial pressure and subsequent right ventricular hypertrophy. 
PPH is typically associated with abnormal proliferation of endothelial and smooth muscle 
cells within the small pulmonary arteries 7. Interestingly, PPH is also strongly associated 
with inflammation, as evidenced by accumulation of inflammatory cells infiltrating into  
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plexiform lesions in the lungs and increased inflammatory cytokines in the circulation of 
PPH patients 8.  Homozygotic deletion of BMPRII in mice causes an embryonic lethal 
phenotype 9, while heterozygotic BMPRII+/- mice show increased susceptibility to 
pulmonary hypertension in response to an inflammatory stress 10. These results provide a 
link between BMPRII mutation or haplo-insufficiency and PPH as well as an association 
between inflammation and PPH.  However, there is no published literature showing that 
BMPRII mutation or decreased BMPRII expression causes inflammation and 
atherosclerosis.  
  
 The effects of BMPRII and BMPs seem to be cell type- and vascular bed- specific.  
Recently, BMPRII knockdown by siRNA was shown to increase apoptosis in human 
pulmonary aortic ECs 11. On the other hand, BMPRII knockdown in human pulmonary 
aortic smooth muscle cells (PASMC) inhibited apoptosis induced by BMP4/7 by 
mechanisms dependent on activation of the caspases-3, 8 and 9 12.  However, these 
studies did not examine whether BMPRII knockdown induces inflammation. Whether 
BMPRII knockdown causes apoptosis has not been examined in the current study, but 
BMP4 itself showed no significant effect on cell proliferation or apoptosis in ECs (data 
not shown).  Even within the same pulmonary arterial bed, smooth muscle cells from 
peripheral and proximal arteries respond differently. BMP4 treatment increased 
proliferation of peripheral smooth muscle cells, but it inhibited it in proximal smooth 
muscle cells of pulmonary arteries 13.  
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 The mechanism by which BMPRII knockdown stimulates ICAM-1 induction and 
subsequent monocyte adhesion in ECs is not known.  However, we propose that the loss 
of BMPRII may unleash the signaling proteins that normally bind to the receptor, 
resulting in uncontrolled activation of inflammatory pathways.  BMPRII is a protein 
(1,038 amino acids) with an extracellular BMP binding domain, a single transmembrane 
domain and a long cytoplasmic domain.  The cytoplasmic domain (866 amino acids) 
contains a serine/threonine protein kinase domain followed by a C-terminal tail.  
Interestingly, this long cytoplasmic domain is unique to BMPRII and not found in other 
members of the TGFβ receptor superfamily.  Moreover, the cytoplasmic domain has been 
shown to bind various signaling proteins, cytoskeletal components and metabolic 
enzymes 14. Among notable ones are p50b NFκB protein, MAP3K8, LIM kinase-1 and c-
Src protein tyrosine kinase 14-16. For example, the C-terminal tail interacts with c-Src, and 
the association has been shown to downregulate the Src tyrosine kinase activity 16.  More 
interestingly, BMPRII mutations truncating the C-terminus, as found in PPH patients, 
increase c-Src activity and subsequent proliferation of smooth muscle cells 16.  Perhaps, 
BMPRII, much like caveolins 17, serves as a docking protein in normal unstimulated 
conditions, holding the signaling proteins in an inactive state. When BMPRII level is 
decreased or its C-terminal is mutated or truncated as in the cases of PPH patients, the 
normally sequestered signaling proteins may be released and activated.  Similarly, when 
BMPRII is knocked down by siRNA or its level is decreased in ECs in advanced 
atherosclerotic lesions, the signaling molecules that are normally sequestered by the 
receptor may be released and activated, leading to a vicious cycle of ICAM-1 induction, 
monocyte adhesion, and eventual atherosclerosis development. In the continued presence 
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of disturbed flow and other risk factors for atherosclerosis such as hypercholesterolemia, 
hypertension, diabetes and smoking, atherosclerotic lesions may progress and BMPRII 
expression level decreases, which can further exacerbate inflammation and 
atherosclerosis.   
  
 Downregulation of BMPRII has been shown in familial and sporadic primary 
pulmonary hypertension as well as in some types of cancers such as prostate and bladder 
cancers. However, it has not been shown that atherosclerotic plaques also lose BMPRII 
expression. It is very possible that a proliferative cell state may be responsible for down 
regulation of BMPRII expression because proliferation is one of the phenotypes that are 
in common among these three areas of research: pulmonary hypertension, cancer and 
atherosclerosis. However, we are suggesting that inflammatory cytokines also decrease 
BMPRII expression in endothelial cells. Here, we have shown that pro-inflammatory 
cytokines, TNFα and LPS, decrease BMPRII expression in HUVECs.  Several reports of 
BMPRII down regulation have been reviewed, particularly in pulmonary hypertension 
and cancer research2,6, 18, 19-21.  In this study, we also showed, using human coronary 
arteries with various atheroma developments, that atherosclerotic conditions 
downregulate BMPRII expression.  
  
 Taken together, we are suggesting a new hypothesis that disturbed flow begins 
inflammation, mediated by BMP4, which initiates foam cell formation. This increases 
secretion of pro-atherogenic factors and cytokines, and this, along with other atherogenic 
risk factors, including hypercholesterolemia, hypertension, and diabetes, is responsible 
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for decreasing BMPRII expression. As we showed with BMPRII knockdown studies, 
decreased BMPRII expression induces secondary inflammation, which accelerates 
atherosclerosis.  Figure 7.1 illustrates our overall hypothesis.  
  
 Based on our hypothesis, we still need to show that pro-atherogenic cytokines 
other than TNFα and LPS or atherogenic risk factors including hypercholesterolemia, 
hypertension, or diabetes, may be responsible for downregulation of BMPRII expression 
and accelerated atherosclerosis.  Atherosclerosis is a long term disease process which 
involves risk factors such as hypertension, age, smoking, and hyperlipidemia. Also, other 
risk factors that could contribute to further understanding of vascular pathology include 
markers of inflammation and growth factors. In this study, we showed only the effects of 
TNFα and LPS on BMPRII expression; however, in future studies, we will need to 
determine the effect of various kinds of  cytokines such as interlukin family members 
(IL-2, IL4, IL-6, IL-8, IL-10, IL-1α, IL-1β), vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF), interferon-γ (IFNγ), and monocyte chemotactic protein-1 
(MCP-1). Secondly, we will need to address how important other risk factors such as 
hyperlipidemia and hypertension are in regulating BMPRII expression as well as to what 
extent BMPRII contributes in the protective role during atherogenesis. 
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Figure 6.1. Overall hypothesis.  Disturbed flow begins inflammation, mediated by 
BMP4, which initiates foam cell formation. This increases secretion of pro-atherogenic 
factors and cytokines, and this, along with other atherogenic risk factors, including 
hypercholesterolemia, hypertension, and diabetes, is responsible for decreasing BMPRII 
expression. As we showed with BMPRII knockdown studies, decreased BMPRII 
expression induces secondary inflammation, which accelerates atherosclerosis. 
 
  
 Furthermore, there may be a new mechanism involved in the downregulation of 
BMPRII. There has been increasing evidence that microRNAs play a crucial role in cell 
type development and chronic diseases. New knowledge about the functional role of 
microRNAs (miRNAs) is revolutionizing cell biology and will have a major impact on 
biomedical research and novel therapeutic opportunities. MiRNAs are a recently 
discovered class of endogenous, small, noncoding, single-stranded RNAs of 22 
nucleotides that regulate about 30% of the encoding genes in the human genome. So far, 
about 400 miRNAs have been identified and as many as 1000 miRNAs are estimated. 
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However, the role of miRNAs in vascular disease is currently completely unknown. To 
date, there has been only one paper regarding miRNA and atherosclerosis by Ji et. al22. 
They ran miRNA microarray analysis using rat miRNA array probes from a carotid artery 
balloon injury model. As we used siRNA to knock down BMPRII expression, it is 
possible that atherosclerotic conditions may increase miRNA and then downregulate 
BMPRII. We searched miRNA hits from human BMPRII sequence, and there were 12 
miRNAs predicted to bind (http://microrna.sanger.ac.uk). Certainly, we need to 
accumulate more data on miRNA profiles in atherosclerosis, and we also need to verify 
which miRNA may be responsible for down regulation of BMPRII.   
 
 We are suggesting that one of the mechanisms by BMPRII knockdown induces 
inflammation is by releasing its binding proteins. Although there had been studies of the 
cytoplasmic domain of BMPRII that have shown it to bind various signaling proteins, 
cytoskeletal components and metabolic enzymes 14-16, there is no data on endogenous 
binding protein profiles specifically in endothelial cells. Therefore, we are planning to 
pursue proteomics studies after pulling down binding proteins of BMPRII.  
 
 Also, we have obtained global BMPRII heterozygote mice, and we are crossing 
these with ApoE knock out mice to study the development of atherosclerosis. We will use 
both a high-fat diet induced atherosclerosis model as well as a partial carotid artery 
ligation model for neointima formation. These animal models will give us more 
information about how BMPRII is protective for atherogenesis.  
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 In conclusion, these studies support the hypothesis that oscillatory shear stress 
increases BMP4 expression which induces inflammation through a ROS-dependent 
pathway. Moreover, atherogenic conditions, such as pro-atherogenic cytokines and 
several risk factors, decrease BMPRII expression which further increases inflammation 
and atherosclerosis.  
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